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Fakultät für Angewandte Naturwissenschaften, Lehrstuhl für Pharmamanagement
vorgelegt von: Christian Lamping aus Köln
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Sciences at TH Köln and the Faculty of Economics at the University of Rostock. Es-
pecially the enlightening discussions with Felix Wolfrum and Fynn Strohecker helped
me a lot. Moreover, I have greatly benefitted from discussions with Peter Bell, Frank
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Introduction
Increasing health expenditure and the efficient allocation of resources in the field
of healthcare are subject to continuous discussion worldwide (OECD, 2019b; World
Health Organization (WHO), 2019). Focussing on Germany, this dissertation con-
tributes to the debate by analysing the effect of behavioural aspects on the decision-
making in healthcare. The objective is to determine factors influencing the perception
of the value of health in Germany. The dissertation at hand comprises three articles.
The first study analyses factors potentially affecting the outcome of the German
pharmaceutical price negotiations since the introduction of the Act on the Reform of
the Market for Medicinal Products (AMNOG) in 2011 (see Federal Ministry of Health,
2016 for further information on the AMNOG regulation). A total of 187 pharmaceu-
ticals that completed the AMNOG process from 2011 to 2017 are analysed. In line
with previous studies (see Lauenroth & Stargardt, 2017; Radic, Haugk, & Radic,
2018; Theidel & von der Schulenburg, 2016), only a small effect of the (additional)
benefit of the pharmaceutical on the price negotiation is found. However, the results
of the study show that the price freely set by the manufacturer before the negotiation
(launch price) has a major impact on the negotiated price. On average, the nego-
tiated price is 80.3% (median 83.3%) of the launch price. Moreover, renegotiating
has a positive effect on the outcome, while a decision made by the arbitration board
decreases the premium.
Results of the first study suggest that factors besides the actual benefit of the
pharmaceutical affect its evaluation. Decisions regarding the value of pharmaceuticals
(pharmaceutical prices) in Germany are made by official institutions on behalf of
the population. These decisions on behalf of the institutions are, in turn, made by
individuals acting as representatives. The aim of the second study is, therefore, to
shed some light on the factors influencing the preferences of individuals.
A survey on German subjects was conducted with a total of 1,199 people par-
ticipating. Queried subjects were asked to state their willingness to pay for a new
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pharmaceutical. Data indicates that the participant’s perception of the pharmaceu-
tical’s benefit strongly affects their willingness to pay. However, besides the benefit,
characteristics of the participants seem xto influence the willingness to pay as well.
Results show a higher payment if the queried subjects are (a) covered by private insur-
ance, (b) state a higher willingness to consume, (c) have more conservative values, and
(d) express social security to be less important. Furthermore, providing information
on the price of the pharmaceutical to some of the participants (2/3 of the cases) leads
to a higher amount of money these participants are willing to pay. Results of this
survey are in line with the first study. The perception of the value of a pharmaceutical
seems to be influenced by factors beyond its actual benefit.
While the first two studies focus on pharmaceuticals, a third study was conducted
to determine whether the evaluation of health, in general, is affected by factors besides
the actual benefit of the intervention. Focussing on Germany, this study contributes
by providing a survey of the determinants of willingness to pay for healthcare in the
literature. Results show socio-economic and health characteristics of the participants
to affect the willingness to pay (e.g. income, health state). Moreover, stated prefer-
ences are found to depend on the survey methodology, such as the survey form and
the elicitation method. The reviewed studies contain three overarching topics: disease
treatment, prevention and health insurance. Interestingly, in the literature examined,
certain effects are found for two of the three topics in several studies each. It is only
for a specific topic that the relationship between willingness to pay and the respective
determinant cannot be proven (e.g. health status and willingness to pay for preven-
tion). Furthermore, it is noticeable that some determinants are not even examined
for certain topics (e.g. risk perception and willingness to pay for health insurance).
Results of this dissertation indicate that the perception of the value of health in
Germany is affected by determinants besides the (perceived) benefit of the interven-
tion. On an institutional level, the first study finds the launch price to influence
the value assessment. In the second study, individual characteristics like conservative
values are found to affect preferences in willingness to pay studies for pharmaceuti-
cals. Results of the literature review also confirm these effects for the general area of
health. Furthermore, in addition to the study participants’ socio-economic and health
characteristics, the influence of the study methodology on the surveyed preferences




Impact of the Launch Price –
An Analysis of German AMNOG
Early Benefit Assessment Data*
1.1 Introduction
Average health spending of the OECD countries corresponds to 8.31% (median:
8.28%) of the country’s gross domestic product; and 16.75% (median: 14.67%) of
this derives from pharmaceuticals (OECD, 2019a, 2019c). Moreover, since effective
drugs are in high demand, national healthcare systems often struggle with the question
of appropriate pricing. On the one hand, there is a social desire for low pharmaceuti-
cal expenses. On the other hand, high prices (i.e. high prospective gains) which are
anyway in the interest of the firms also provide incentives to invest in research and
development which is socially desired. As a consequence pharmaceutical prices are a
notoriously contentious topic (Steele, 1962, 1964; Scherer, 2004; Stiglitz & Jayadev,
2010; Parker-Lue, Santoro, & Koski, 2015; Frakt, 2019) and have become a major
topic in the political discussion worldwide, causing the World Health Organization to
call for more transparency regarding medicine prices (t’ Hoen, 2019).
This paper contributes to the discussion by analysing the pricing process for new
pharmaceuticals in Germany, a reference market for the European Union (Vogler &
Martikainen, 2015). The focus on Germany is made not only because of its wider
∗This chapter is based on Böhler, Lamping, and Wichardt (2019).
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relevance. Also a new procedure to determine pharmaceutical prices – the Act on
the Reform of the Market for Medicinal Products (AMNOG) – was introduced in
2011 with the intent to tie prices closer to benefits. In order to achieve this, price
negotiations are now based on an early benefit assessment of the respective drug’s
additional benefit compared to the appropriate comparative therapy (comparator).1
According to the new procedure, manufacturers are allowed to freely price their new
product during the first year after its release. The negotiated price, then, applies for
any future years (Federal Ministry of Health, 2016).
The procedure, however, keeps being criticised for still granting only minor or no
influence to fundamentals, most of all the drug’s additional benefit (Aerztezeitung,
2014). In fact, previous studies (i.e. Lauenroth & Stargardt, 2017 and Theidel &
von der Schulenburg, 2016) come to the conclusion that the additional benefit and
other factors such as therapeutic area, orphan drug status, and appropriate compar-
ative therapy alone do not fully explain the negotiated reimbursement price. With
the present study, we extend earlier works in two ways. First of all, we use a broader
and more current dataset. Moreover, we provide an analysis of the relation between
the price freely set by the manufacturer and the price negotiated between the manu-
facturer and the Statutory Health Insurance Funds. The results indeed suggest that
caution regarding the effectiveness of the new negotiation process in terms of reaching
a closer tie between prices and actual benefits is warranted.
1.2 Methods
Sample Selection
From January 1st 2011 to December 31st 2017, the Federal Joint Committee (Federal
Joint Committee, 2019b) conducted 327 early benefit assessments (EBAs), which are
the basis of our dataset. 309 of these 327 EBAs completed the assessment by the
Federal Joint Committee and were, hence, eligible for our study. Of these 309 EBAs,
a total of 122 EBAs had to be excluded for various technical reasons. The final sample
therefore contains 187 EBAs. Figure 1 illustrates the selection process.
1Negotiating parties are the pharmaceutical manufacturer and the National Association of Statu-




Exclusion of conducted EBAs by procedural status (n=18):
a) defered (n=1)
b) ceased (n=8, thereof 5 opt-out)
c) released (n=9, thereof 4 orphan drugs and 2 opt-out)
Completed EBAs (n=309)
Exclusion of completed EBAs for the following reasons (n=122):
a) listed reference price available (price determinded without negotiation)
(n=4)
b) orphan drug (no comparator available): (n=73, thereof 5 opt-out)
c) opt-out (pharmaceutical withdrawn from the market) (n=35, thereof 5
orphan drugs)
d) no annual therapy costs available (n=1)
e) no annual comparator costs available (n=15, thereof 1 with no annual
therapy costs available)
f) no patient group size available (n=1, thereof 1 with no annual therapy
costs available)
Analysed EBAs (n=187)
Figure 1: Sample selection: Exclusion criteria and number of excluded EBAs in




Data regarding the early benefit assessment were extracted from the publicly avail-
able website of the Federal Joint Committee (Federal Joint Committee, 2019b). These
data contain extent and certainty of the additional benefit as assessed by the man-
ufacturer, the Institute for Quality and Efficiency in Health Care (IQWiG) and the
Federal Joint Committee, as well as the annual costs of therapy per patient, the pa-
tient group size, and the appropriate comparator. Moreover, pharmaceutical prices
before and after the negotiation were extracted from the official German price database
Lauer-Taxe (Lauer-Taxe, 2019). Publicly available information on financial data was
gathered from the ifo Business Climate Index (ifo Institute, 2019) and finanzen.net
(Finanzen.net GmbH, 2019).2
Variables
Dependent Variable: For our analysis, we use the negotiated premium on the com-
parator price as a target variable. This is defined as the relation between the new
pharmaceutical’s annual cost of therapy per patient and the respective comparator’s
annual cost of therapy per patient. For both costs, we use the values defined by the
Federal Joint Committee. This approach is consistent with the intentions of AMNOG,
creating a reimbursement price, which represents the additional benefit assessed over
the appropriate comparator (Federal Joint Committee, 2019a). The method was al-
ready used by Lauenroth and Stargardt (2017).
negotiated premium =
pharmaceutical’s annual costs per patient after the negotiation
comparator’s annual costs per patient
(1)
Independent Variables : The dataset includes a total of 18 explanatory variables. A
summary of these can be found in Table 1.
Similarly to the negotiated premium, we use the ratio of the pharmaceutical’s
annual costs per patient before the negotiation to the comparator’s annual costs per
patient, henceforth referred to as launch premium.
launch premium =
pharmaceutical’s annual costs per patient before the negotiation
comparator’s annual costs per patient
(2)
2In organising the data, we greatly benefitted from Blankart and Stargardt (2017) who kindly
provided a reference data set.
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Independent Variable Inclusion Citeria
launch Ratio of the pharmaceutical’s annual costs per patient before
the negotiation to the comparator’s annual costs per patient.
cost Annual therapy costs per patient for the new pharmaceutical
defined by the Federal Joint Committee.
comparator cost Annual therapy costs per patient for the respective appropriate
comparative therapy (comparator) defined by the Federal Joint
Committee.
extent additional benefit The extent of the additional benefit compared to the appropri-
ate comparative therapy (comparator) defined by the Federal
Joint Committee.
certainty additional benefit The certainty of the additional benefit compared to the appro-
priate comparative therapy (comparator) defined by the Fed-
eral Joint Committee.
extent*certainty (interaction) The product of the extent and certainty of the additional ben-
efit defined by the Federal Joint Committee.
renegotiation Binary variable indicating whether a manufacturer chose to
apply for a reassessment (e.g. due to an extension to a new in-
dication). Reassessment causes a renegotiation (Federal Joint
Committee, 2019a).
arbitration Binary variable indicating whether the pricing decisions were
made by an arbitration board. The independent arbitration
board takes over if both parties cannot agree on a price during
the negotiation (Ludwig & Dintsios, 2016). The dataset con-
tains 47 EBAs with decisions made by the arbitration board.
population size Total target population size of the new pharmaceutical. The
sum of the average sizes of the respective patient groups defined
by the Federal Joint Committee.
headquarter The location of the headquarter of the manufacturer’s parent
company.3
experience process The number of conducted AMNOG processes and AMNOG
negotiations, and the size of the manufacturer (measured by
its total assets (Moeller, Schlingemann, & Stulz, 2004)).4
experience negotiation
company size
limitation Binary variable indicating whether an EBA has a time lim-
itation which causes further assessment in the near future
(Federal Ministry of Justice and Consumer Protection, 2010).
This holds for 31 EBAs.
previous opt-outs The number of previous withdrawals from the German market
(also called opt-out) (Social Security Code V (SGB V), 2012)
made by a manufacturer.
ifo business climate index The annual ifo business climate index (ifo Institute, 2019) as
a proxy for the general economic situation during the negotia-
tion.
hearing participants The number of participants in the hearing (vfa. Die forschen-
den Pharma-Unternehmen, 2018) as a proxy for the perceived
importance of respective pharmaceutical.
discrepancy assessed benefit The effect of the discrepancy between the manufacturer’s and
the Federal Joint Committee’s assessed extent of the additional
benefit on the negotiation.
3 See French and Poterba (1991) for the influence of home bias and Chang (2006) for cultural
differences in negotiation techniques.
4 See Thompson (1990) for the influence of experience on the negotiation performance.




For each pharmaceutical one specific price is negotiated. However, for the benefit
assessment, the patient population of a certain pharmaceutical is divided into different
patient groups. This leads to divergent assessed additional benefits, annual costs of
therapy (also for comparator) and patient group sizes, within one pharmaceutical.
For the analysis, we weigh the annual costs of therapy per patient of each patient
group with the ratio between its population size and the sum of the population size
of all patient groups of the respective EBA. We use annual costs of treatment per







Similarly, we calculate the extent of the additional benefit and the certainty of
the additional benefit for each EBA using the additional benefit assessed by the Fed-
eral Joint Committee. The necessary transformation of the ordinal benefit assess-
ments to cardinal ones is conducted using the following point scale in Table 2. See
Hammerschmidt (2017) for a similar approach.





· extent additional benefiti
(4)





· certainty additional benefiti
(5)
For the purpose of the analysis an ordinary least squares regression was conducted.
Because of the distribution of the following variables: negotiated premium, launch
premium, costs of the pharmaceutical, costs of the comparator, and population size,
we use the logarithm of these five variables. All other variables are kept at their
initial state. Several sensitivity analyses were conducted to control for our premises
(see Appendix A.1). The core results remain the same for all models. All analyses
were conducted using Stata 15.1.
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Extent Benefit Point Scale Certainty Benefit Point Scale
major 6 proof 4
considerable 5 indication 3
non quantifiable 4 hint 2
minor 3 n/a 1
no added benefit 2
lesser benefit 1
Table 2: Transformation of ordinal additional benefit into a cardinal point scale.
1.3 Results
The following section is divided into three parts. The results of the (1) descriptive
analysis, (2) regression analysis, and (3) an analysis of the assessment differences be-
tween the Federal Joint Committee, IQWiG, and the manufacturer.
Descriptive Analysis
The 187 EBAs used in our study were submitted by 53 manufacturers (average: 3.53,
median: 1; min: 1, max: 19), with more than half of the manufacturers (N = 28)
having submitted only one EBA. Moreover, the predominant group of EBAs are phar-
maceuticals for oncological diseases (N = 68). In fact, the top three therapeutic areas
(oncological diseases N = 68; infectious diseases N = 29; metabolic diseases N = 22)
make up for 64% of the EBAs.
Furthermore, our data reveal a difference between the manufacturers’ stated ex-
pectation about the assessment, and the assessments made by IQWiG and the Federal
Joint Committee. In particular, IQWiG and the Federal Joint Committee assess the
additional benefit lower. A summary of the extent of the additional benefit by as-
sessor can be found in Table 4; see Fischer and Stargardt (2014) for a more detailed
discussion of the topic.
Regarding the actual pricing, we find that the average premium on the compara-
tor’s cost before the negotiation (launch) is 526.4%. During the negotiations, this
gets reduced to approximately 80.3% of the initial premium (average final premium:
422.7%). These values are strongly influenced by some outliers, though. The median





A linear regression was conducted to analyse the effect of various determinants on the
German pharmaceutical price negotiation. The results are summarised in Table 3.
Model 1 (M1), is based on all independent variables except for the launch premium;
a full analysis is reported in Model 2 (M2). Model 3 (M3) reports results from a
regression including only cost variables; Model 4 (M4) in turn focusses on the sole
influence of the launch premium. Finally, Model 5 (M5) analyses the effect of the
additional benefit - and only that - on the negotiated premium. The main results of
our analysis – excluding variables with a statistically insignificant effect – are presented
as Model 6 (M6) in the sequel.
premium M1 M2 M3 M4 M5 M6
17 iv 18 iv costs launch benefit final
launch 0.977∗∗∗ 0.973∗∗∗ 0.960∗∗∗
cost 0.977∗∗∗ (omitted) 0.983∗∗∗
comparator cost -0.971∗∗∗ 0.006 -0.970∗∗∗
extent additional benefit 0.170∗ 0.170∗ 0.549 0.172∗
certainty additional benefit 0.141 0.141 0.296 0.151
extent*certainty (interaction) -0.056 -0.056 -0.089 -0.058
renegotiation 0.221∗∗∗ 0.221∗∗∗ 0.224∗∗∗
arbitration -0.086 -0.086 -0.120∗∗
population size -0.004 -0.004
headquarter 0.012 0.012
experience process 0.028 0.028
experience negotiation -0.025 -0.025
company size 0.000 0.000
limitation -0.009 -0.009
previous opt-outs -0.064 -0.064
ifo business climate index 0.006 0.006
hearing participants 0.003 0.003
discrepancy assessed benefit 0.006 0.006
constant -1.518 -1.518 -0.351∗∗∗ -0.226∗∗∗ -0.840 -0.690∗∗∗
N 177 177 187 187 187 187
R-sqr 0.955 0.955 0.936 0.935 0.131 0.948
Table 3: Regression results of M1-M6; Factors influencing the negotiated premium;
M1 and M2 controlled for therapeutic area; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.
Launch Premium
A first analysis shows that the negotiated premium is strongly correlated with the
annual costs of the new pharmaceutical (+0.977; p < 0.001) and the annual costs
of the comparator (-0.971; p < 0.001); (see M1, Table 3). However, including the
launch premium leaves the effect of both, the costs of the new pharmaceutical, and
the comparator insignificant. Thus, the launch premium itself seems to have a strong
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effect on the negotiated premium (see M2, Table 3).
Comparing the effect of cost of the pharmaceutical and comparator cost on the
negotiated premium (see M3, Table 3) with the sole effect of the launch premium
on the negotiated premium (see M4, Table 3), both regression models come to very
similar results. The correlation between the launch premium and the negotiated
premium can be seen in Figure 2.
Figure 2: Log OLS of the premium before and after the negotiation.
Note in particular that the goodness of fit for Model 4 (M4, Table 3) is 93.5%,
suggesting that the launch price explains a large share of the eventual premium.
Result 1 The launch premium has a strong correlation with the eventually negotiated
premium (M4; p < 0.001).
Additional Benefit
By contrast, Model 5 (M5, Table 3), which only considers the additional benefit of the
new pharmaceutical, has only a goodness of fit of 13.1% with no statistically significant
impact of the variables. Once we take the pharmaceutical costs and comparator costs
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(or launch premium) as well as all other variables into account, the extent of the
additional benefit becomes statistically significant (+0.170; p < 0.05; see M1 or M2,
Table 3).
Result 2 The extent of the additional benefit of the new pharmaceutical shows only
a small correlation with the negotiated premium which also shows a lower degree of
statistical significance (M5, p >= 0.05; M6, p < 0.05).
Renegotiation
For some pharmaceuticals (N = 69) renegotiation took place, e.g. due to an extension
to a new indication. In Model 6 (M6, Table 3), we find a positive effect of this
renegotiation on the premium.5
Result 3 Renegotiation (e.g. due to adding a new indication) correlates positively
with the negotiated premium (M6, p < 0.001).
Decision by Arbitration Board
Including the launch premium, the additional benefit and a binary defining whether
it is a renegotiation, results suggest a lower negotiated premium (-0.120; p < 0.01) if
the decision is made by an arbitration board (see M6, Table 3). However, the effect
of a decision by the arbitration board is not significant in the full model (M1 or M2,
see Table 3).
Result 4 If the pricing decision is made by an arbitration board, the effect on the
negotiated premium is negative (M6, p < 0.01).
Assessment Differences
Finally, we want to emphasise that the data show a tangible discrepancy between
the three different assessments of the additional benefit (Federal Joint Committee,
IQWiG, manufacturer; see Table 4). In fact, a two-sided paired t-test, and a Wilcoxon
matched-pairs signed-ranks test (Wilcoxon, 1946) show that manufacturers system-
atically provide more favourable assessments of their products than the Federal Joint
Committee (p < 0.001).
However, to our surprise we find that the assessment of the Federal Joint Com-
mittee actually shows the highest explanatory power regarding launch prices (OLS
5An additional confirming analysis, taking into account only the first assessment of each pharma-




Extent Additional Benefit Manufacturer IQWiG Federal Joint Committee
lesser benefit 0 1 0
no added benefit 12 110 96
minor 21 38 44
non quantifiable 44 20 30
considerable 56 11 11
major 48 1 0
total 181 181 181
Table 4: Comparison of the assessed extent of the additional benefit by the manu-
facturer, IQWiG and the Federal Joint Committee. Number of assessments with a
certain extent of the additional benefit, by organisation.
regression: manufacturer: 0.254, p < 0.001, R-sqr=9.6%; Federal Joint Committee:
0.383, p < 0.001, R-sqr=13.8%).6
This is at least puzzling, as the assessment of the Federal Joint Committee is made
only after the launch price is set using data provided by the manufacturer. Assuming
that the Federal Joint Committee does not use the pharmaceutical’s launch price
itself for the evaluation of the drug’s benefit, results suggest that manufacturers at
least partly decouple prices from data and make strategic pricing decisions. While
in itself is not surprising the decoupling of information (about the benefit) and the
price setting contradicts the general idea of the AMNOG procedure, which aims to tie
benefits and prices more closely. Moreover, our previous results show that the launch
premium affects the eventually negotiated premium. Manufacturers decoupling benefit
and price and setting prices strategically suggests that there is further room for social
welfare improvement in the procedure.
Result 5 Manufacturers assess their pharmaceutical more positively than IQWiG and
the Federal Joint Committee. Moreover, the assessment by the Federal Joint Commit-
tee shows a stronger correlation with the launch price than the manufacturer’s own
assessment.
6We find no statistically significant difference – using a generalised Hausman specification test
(Hausman & Taylor, 1981) (prob > chi2 = 0.0582) – regarding the effect of the benefit assessments




In this paper, we have presented the results from an analysis of the pricing process
of 187 innovative pharmaceuticals in Germany which were introduced between 2011
and 2017. While the data confirm a small but tangible dependence of eventual price
premiums on the actual additional benefit of the respective pharmaceutical, they also
provide support for the claim that eventual prices are only weakly tied to fundamentals
(i.e. actual additional benefit of the drug). Instead, the launch price set freely by the
manufacturer in the first year has a far stronger impact on the negotiated premium in
our data set, both in terms of parameter size and level of statistical significance. While
we can of course only speculate about reasons, a likely explanation seems to be that
manufacturers simply exploit anchoring effects when setting prices for the first year
(cf. Ariely, Loewenstein, & Prelec, 2003; Galinsky & Mussweiler, 2001; Mussweiler,
Strack, & Pfeiffer, 2000; Tversky & Kahneman, 1974).
Moreover, a comparison of the additional benefit assessments by the manufactur-
ers, IQWiG and the Federal Joint Committee suggests that manufacturers provide
assessments with a systematically higher additional benefit of their pharmaceuticals.
Further analysis leads to the result that the official assessment by the Federal Joint
Committee has the highest explanatory power regarding launch prices freely set by
the manufacturers in the first year.
While in itself not entirely surprising, this result, to us, still seems relevant from a
policy perspective. If firms use overly positive reports on their pharmaceuticals to set
their launch prices and if these are what effectively determines later prices, further
regulation or at least a less lenient bargaining strategy of official institutions might
be justified or even called for.
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Chapter 2
Determinants of Willingness to
Co-Pay for Pharmaceuticals –
An Empirical Study on German
Subjects*
2.1 Introduction
Pharmaceutical prices in Germany are negotiated between the drug’s manufacturer
and political institutions on behalf of the population.1 These decisions on behalf of
political institutions and manufacturers are, in turn, made by individuals. Therefore
the individual situation of the decision-maker might influence the decision making for
others (Ifcher & Zarghamee, 2020).
Asking participants for their willingness to pay is one method to elicit preferences
which has become popular in health economics (Ryan et al., 2001; Smith, 2000).
Previous studies (see Ryen & Svensson, 2015 for a review of the empirical literature
on willingness to pay for a quality adjusted life year) analyse participants’ willingness
to pay for certain treatments. However, they mostly focus on the influence of the
treatment’s benefit and control for socio-economic effects (e.g. income). The aim
of this study is to find out whether individual characteristics (e.g. values, opinions)
affect the evaluation of pharmaceuticals. We conducted a survey asking for people’s
∗This chapter is based on Lamping, Boehler, and Wichardt (2020).
1The Act on the Reform of the Market for Medicinal Products (AMNOG) was introduced in 2011
in order to tie pharmaceutical prices closer to their benefit (see Henke, 2014 for further information).
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willingness to pay for pharmaceuticals and determinants potentially influencing their
decision.
In line with previous studies analysing the factors that potentially influence the
pharmaceutical price negotiation in Germany (see Böhler et al., 2019; Lauenroth
& Stargardt, 2017; Radic et al., 2018; Theidel & von der Schulenburg, 2016, for
more details), results of our statistical analysis indeed suggest that the evaluation
of pharmaceuticals by the population is determined by various factors besides the
perceived benefit. Participants’ health insurance (statutory vs private), willingness to
consume, values, need for social security, and information on pharmaceutical prices
affect their willingness to pay.
Therefore, if pharmaceutical prices should be based exclusively on their bene-
fit (efficacy), controlling for the decision-makers’ characteristics should be discussed.
However, further research is necessary regarding the influence of individual factors
on the pricing process. Furthermore, our results raise the question of whether the
evaluation of pharmaceuticals should depend on the people’s preferences. This could
be done by taking not only the pharmaceutical’s benefit but also the characteristics
of the pharmaceutical’s target population into account when defining prices on behalf
of them.
The remainder of this paper is structured as follows: In section 2.2, we describe
our experimental design. Analyses and results are provided in Section 2.3. Section
3.3 concludes with some general comments.
2.2 Survey Design
The aim of this study is to elicit the determinants affecting people’s evaluation of
pharmaceuticals. Therefore, a willingness to pay survey was conducted at three dif-
ferent universities.2 The survey took part from September to October 2019. Data was
gathered using a paper-back questionnaire at the beginning of a lecture. Each session
started with a short introduction after which the questionnaires were handed out to
the students, willing to participate. Responding to our items took about 10 minutes
of subjects’ time in total. Data from 1,199 university students is eligible for analysis.
The questionnaire consists of two parts and can be found in the appendix (Ap-
pendix A.3). The first part accounts for the participant’s socio-economic and health
2We conducted the study at TH Koeln University of Applied Sciences, OWL University of Applied
Sciences and Arts, and Hamm-Lippstadt University of Applied Sciences.
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status3 as well as their satisfaction, priorities, and opinions. In the second part, a
fictitious person having a certain disease is presented, and the efficacy of two (current
and new) pharmaceuticals approved for the respective disease is compared. After-
wards, participants are asked to express their perception of the advantage of the new
pharmaceutical in comparison to the current one, henceforth added benefit. Follow-
ing the question regarding the perceived added benefit, queried subjects are asked
whether they would recommend the new pharmaceutical.
(i) If the participant does not recommend the pharmaceutical, the questionnaire
ends.
(ii) If the participant does recommend the pharmaceutical, information regarding
the price of the current and the new pharmaceutical is given (2/3 of the cases
receive information on the price). Eventually, participants are asked to state
their willingness to pay for the new pharmaceutical.
Effectively we ask for the willingness to co-pay as the German healthcare sys-
tem employs statutory health insurance funds financed by the solidarity community
(Federal Ministry of Health, 2015).4 For the ease of exposition, we refer to it as
willingness to pay.
Our experimental design consists of twelve treatments. The treatments differ in
the following ways: Four different indications (psoriasis, lung cancer, heart failure,
and COPD) are used. Within these four scenarios, there are three different variations
regarding the stated price of the current and the new pharmaceutical (no price stated,
real price stated, and fictitious price stated).
The fictitious price for the new pharmaceutical is the same for all four indications.
It is the average of the real prices of all four new pharmaceuticals. The same applies
to the fictitious price of the current pharmaceutical.
This leads to a total of twelve different treatments, i.e. four diseases multiplied by
three prices each.
Using different indications allows us to analyse framing effects (Tversky & Kahne-
man, 1981). The different price information is used to analyse two effects. The anchor
effect (a higher stated price might cause a higher willingness to pay) (Kahneman,
1992) and the effect of cost awareness as people with a statutory health insurance
3We use the EQ-5D to measure the participants’ generic health status (EuroQol Research Foun-
dation, 2019a).
4Health insurance funds reimburse pharmaceutical expenses, and patients only co-pay a maxi-
mum of e10 per pharmaceutical (Federal Ministry of Health, 2017). If a manufacturer decides to
price its pharmaceutical above the negotiated price, patients have to pay the difference, and therefore
co-payment might exceed e10 (DeutschesApothekenPortal (DAP), 2019).
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(90% of the population, Federal Ministry of Health, 2020) might not have informa-
tion on pharmaceutical prices but only know the relatively small co-payments (Breyer,
Zweifel, & Kifmann, 2003). The described effect of the drug for COPD occurs after
only 24 weeks, while the effect of the drug for heart failure is reported over a period of
two years. These different time periods allow us to test whether a present bias affects
the decision of the queried subjects (O’Donoghue & Rabin, 1999). See Table 5 for
an overview of the twelve treatments. Each participant received only one treatment.
The questionnaires were randomly sorted before the lecture and then distributed in
the lecture hall.
treatment indication price information price new pharmaceutical price current pharmaceutical
treatment 1 psoriasis no price information n/a n/a
treatment 2 psoriasis real price e1,416.62 e206.61
treatment 3 psoriasis fictitious price e2,613.93 e1,310.40
treatment 4 lung cancer no price information n/a n/a
treatment 5 lung cancer real price e8,841.93 e4,983.85
treatment 6 lung cancer fictitious price e2,613.93 e1,310.40
treatment 7 heart failure no price information n/a n/a
treatment 8 heart failure real price e165.14 e24.62
treatment 9 heart failure fictitious price e2,613.93 e1,310.40
treatment 10 copd no price information n/a n/a
treatment 11 copd real price e32.03 e26.52
treatment 12 copd fictitious price e2,613.93 e1,310.40
Table 5: Overview of the twelve treatments. Four indications with three different
kinds of price information. The fictitious price of the new/current pharmaceutical is
the average of the real price of the new/current pharmaceutical price.
2.3 Analyses and Results
Summary Statistics
Our dataset contains responses of 1,199 participants. The participants’ mean age
is 22.7 years (SD of age = 4.2). Women represent 42.4% of the participants. The
majority (93.9%) of the participants are single (not married, divorced, or widowed)
and currently in a bachelor’s degree programme (91.2%). The stated average money
available after rent is e393.0 (SD of income = 217.9).
Average willingness to pay for the twelve treatments is e139 (median: e31) per
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month.5 Table 6 gives an overview of the average and median willingness to pay per
treatment and indication.
treatment indication price information willingness to pay conditional willingness to pay
treatment 1 psoriasis no price information e68; e31 e77; e31
treatment 2 psoriasis real price e159; e76 e181; e76
treatment 3 psoriasis fictitious price e145; e76 e158; e76
treatment 1-3 psoriasis n/a e124; e76 e139; e76
treatment 4 lung cancer no price information e118; e31 e183; e31
treatment 5 lung cancer real price e151; e31 e215; e31
treatment 6 lung cancer fictitious price e201; e31 e334; e31
treatment 4-6 lung cancer n/a e157; e31 e243; e31
treatment 7 heart failure no price information e141; e31 e179; e31
treatment 8 heart failure real price e110; e31 e142; e31
treatment 9 heart failure fictitious price e246; e126 e306; e126
treatment 7-9 heart failure n/a e167; e31 e212; e31
treatment 10 copd no price information e81; e31 e105; e31
treatment 11 copd real price e80; e10 e108; e10
treatment 12 copd fictitious price e154; e76 e207; e76
treatment 10-12 copd n/a e106; e31 e141; e31
treatment 1-12 n/a n/a e139; e31 e180; e76
Table 6: Willingness to pay in Euro (average; median) per treatment and indication.
Willingness to pay: Willingness to pay is assumed to be zero for participants not
recommending the new pharmaceutical. Conditional Willingness to Pay: Analysing
only data of participants who recommend the new pharmaceutical.
Regression Analyses
Linear regression is conducted to analyse effects on the willingness to pay (M1 and M2,
Table 7) and the perceived added benefit (M4, Table 7). The questionnaire contains
Likert-scale items. Therefore, we additionally perform an ordered probit regression to
account for the ordinal type of the dependent variable (willingness to pay and added
benefit) (Daykin & Moffatt, 2002). First, we still treat the independent variables as
interval scaled (willingness to pay: M5; added benefit: M7). Then, we conduct an
ordered probit regression using dichotomous explanatory variables to account for the
ordinal type of these variables (willingness to pay: M6; added benefit: M8). Results
do not change in effect direction (see Appendix B.1.1 and B.1.2). We use logistic
5The participants were able to choose from predefined payments. These payment options were
presented in form of e50 ranges, e.g. e51 to e100. We use the mean value between the lower and
the upper bound. Sensitivity analyses show no difference in results when using the lower or upper
bound.
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regression to analyse, which factors influence the decision of recommending the new
pharmaceutical (M3, Table 7). All analyses are conducted using Stata 15.1.
As only those participants who decide to recommend the new pharmaceutical can
state their willingness to pay, we assume the willingness to pay to be zero for partic-
ipants who do not recommend the new pharmaceutical (M1, Table 7). In a second
model (M2, Table 7) we only consider participants who recommend the new pharma-
ceutical and therefore state a willingness to pay – henceforth conditional willingness
to pay. A two-step Heckman correction, to control for the caused truncation does not
change results (Heckman, 1976, 1979), (see Appendix B.2).
Based on a factor analysis, certain variables are grouped into the following cate-
gories for regression analyses:
(1) Conservative: Higher priorities regarding being able to afford things, being
successful, owning a house, having a happy marriage/relationship, and having
children.
(2) Consume: Willingness to spend on a car, a smartphone, and shoes.
(3) Social security : Importance of the social security system in Germany and whether
it should be decreased or expanded.
(4) System confidence: Perceived circumstances and medical care in Germany.
Willingness to Pay
A regression analysis regarding the queried subjects’ willingness to pay leads to the
following results (see also Model M1, Table 7).
Result 1 The willingness to pay is affected by the following six factors.
The willingness to pay correlates positively with:
(a) The perceived added benefit of the new pharmaceutical in comparison to the
current standard therapy (b=+20.028, p<0.001).
(b) Being more conservative (b=+5.020, p<0.01).
(c) The willingness to spend on consumer products (b=+7.705, p<0.01).
(d) Information about pharmaceutical prices (no price information: b=-83.966, p<0.001;
real price: b=-55.749, p<0.01; fictitious price: reference).
The willingness to pay correlates negatively with:
(e) Being insured by statutory health insurance (not privately insured) (b=-68.499,
p<0.01).
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(f) The stated importance of the German social security system (b=-14.957, p<0.05).
Higher willingness to pay at higher incomes tells us relatively little about par-
ticipants’ needs (See Liebe, Preisendörfer, & Meyerhoff, 2011 presenting results that
income does not affect the general willingness to pay, but the amount of money peo-
ple are willing to pay.) In contrast, our results suggest that the respective partici-
pants have a particular preference for the pharmaceutical in question. For instance,
a comparison of the willingness to pay for the different pharmaceuticals reveals a
substantially higher perceived need for the provision of a drug to treat lung cancer.
Information on the pharmaceutical prices (real or fictitious prices) correlates posi-
tively with the willingness to pay. However, we find no general increase in willingness
to pay with an increase in the stated price. The fictitious price is higher than the
real price for all indications but “lung cancer”. However, for the indication “lung
cancer” the treatment 6 (fictitious price) and for the indication “psoriasis” the treat-
ment 2 (real price) yield the highest willingness to pay. Stating higher prices for the
indications “heart failure” and “COPD” leads to a higher willingness to pay of the
participants.
Note that the higher willingness to pay of participants with private health insur-
ance is to be taken with a grain of salt as in the German healthcare system in prin-
ciple only people with statutory health insurance need to co-pay for pharmaceuticals
(Busse, Blümel, Knieps, & Bärnighausen, 2017; Wissen-PKV.de, 2020). Therefore, it
is unclear whether these participants thought that they should co-pay themselves or
state a monetary value which the statutory health insured population would pay.
Considering only those questionnaires with a recommendation (N=870), the average
conditional willingness to pay for the twelve treatments is e161 (median: e51) per
month. Regression analysis results (M2, Table 7) match those of the previous regres-
sion analysis (M1, Table 7) except for two differences. The perceived added benefit
of the new pharmaceutical has no statistically significant influence on the level of
willingness to pay for participants who already recommend the new pharmaceutical
(b=+2.101, p>=0.05). Also, women’s willingness to pay is lower (b=-39.171, p<0.05).












(M1) (M2) (M3) (M4)
willingness to pay conditional willingness to pay recommendation added benefit
b/se b/se or/se b/se
lung cancer reference reference reference reference
psoriasis -76.487∗∗∗ -116.385∗∗∗ 1.771∗ 1.879∗∗∗
(21.11) (25.36) (0.45) (0.16)
heart failure -2.989 -42.599 1.692∗ 0.506∗∗
(20.09) (25.11) (0.37) (0.16)
copd -61.424∗∗ -114.722∗∗∗ 1.581∗ 0.219
(20.23) (25.82) (0.34) (0.16)
fictitious price reference reference
no price information -83.966∗∗∗ -114.035∗∗∗
(17.28) (20.94)
real price -55.749∗∗ -76.267∗∗∗
(17.30) (20.91)
added benefit 20.028∗∗∗ 2.101 1.798∗∗∗
(3.67) (5.12) (0.08)






social security -14.957∗ -15.962∗ 0.230∗∗∗
(6.28) (7.88) (0.05)
system confidence 6.884 6.263 0.114∗∗∗
(4.22) (5.29) (0.03)
female -25.844 -39.171∗ -0.262∗
(14.84) (17.94) (0.12)
constant -16.153 137.651 0.069∗∗∗ 3.987∗∗∗
(64.95) (82.24) (0.02) (0.38)
N 1032 802 1123 1127
M1, M2 and M4: Linear Regression; M3: Logistic Regression; or: Odds Ratio (Exponentiated coefficients)
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001
Table 7: Regression analysis. Factors influencing willingness to pay, recommendation and perceived added benefit.
M1: Willingness to pay is assumed to be zero for participants not recommending the new pharmaceutical. M2: Analysing
only data of participants who recommend the new pharmaceutical. M3: Recommendation of the new pharmaceutical.
M4: Perceived added benefit of the new pharmaceutical in comparison to the current standard therapy.
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Recommendation and Perceived Benefit
Recommendation: Only participants recommending the new pharmaceutical were al-
lowed to state their willingness to pay. A total of N=870 participants recommended
the new pharmaceutical while N=262 did not. This questionnaire design was cho-
sen to simulate the hurdle created by the introduction of the Act on the Reform of
the Market for Medicinal Products (AMNOG) in 2011. Since then, the manufacturer
needs to provide evidence that its new pharmaceutical has an added benefit compared
to the respective current therapy in order to negotiate a premium on the price of the
current standard therapy (Social Security Code V (SGB V), 2020).
Analysing the queried subjects’ decisions to recommend the new pharmaceutical
leads to the following results, which can be found in Model 3 (M3), Table 7.
Result 2 The odds that a participant recommends the new pharmaceutical are affected
by the following two factors:
(a) The higher the perceived added benefit of the new pharmaceutical in comparison
to the current standard therapy, the higher the odds of a recommendation of the
new pharmaceutical (or=+1.798, p<0.001).
(b) The indication “lung cancer” has a negative impact on the odds of a recommen-
dation of the new pharmaceutical (psoriasis: or=+1.771, p<0.05; heart failure:
or=+1.692, p<0.05; COPD: or=+1.581, p<0.05; lung cancer: reference).
Perceived Benefit: Results of our analysis (Model 1, Table 7) show that the decision to
recommend the new pharmaceutical strongly depends on the perceived added benefit.
An analysis of the factors influencing the perception of the benefit can be found in
Model 4 (M4), Table 7.
Result 3 The perceived added benefit of the new pharmaceutical in comparison to the
current standard therapy correlates positively with:
(a) the stated importance of the German social security system (b=+0.230, p<0.001)
and
(b) the perceived confidence in the German system (b=+0.114, p<0.001).
Summarising, we observe a positive correlation between confidence in the German
(healthcare) system and its social security and the perceived added benefit of the
new pharmaceutical. The perceived benefit, in turn, has a significant impact on the
willingness to recommend a new drug. The amount of the additional payment depends
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essentially on the perceived benefit, the type of insurance (statutory or private), the
willingness to consume, values (conservative or not), attitudes towards social security,
and the prices stated for the pharmaceuticals.
2.4 Concluding Remarks
In this paper, we have presented the results from an analysis of survey data regarding
the determinants of willingness to pay for pharmaceuticals in Germany.
Study subjects’ median willingness to pay is e31 (and using the lower bound
e11), which is slightly above the legally defined co-pay maximum of e10 (Federal
Ministry of Health, 2017).6 While in itself not entirely surprising, the results regarding
the determinants affecting the willingness to pay, to us, seem relevant from a policy
perspective.
People seem to evaluate a pharmaceutical by its perceived benefit. However, we
find the participants’ preferences to be strongly affected by their individual charac-
teristics. Moreover, subjects who received information on the pharmaceutical prices
(2/3 of the cases) were willing to pay a higher amount. A natural guess to us seems
to be that this former result is caused by the missing information on pharmaceutical
prices at least by people with a statutory health insurance who are only aware of the
relatively small amount of co-payment (Breyer et al., 2003). However, we find no
relationship between the height of the stated price and the willingness to pay.7
The results emphasise that people’s perception of a pharmaceutical’s value is not
only defined by its medical benefit. In the context of the pharmaceutical price ne-
gotiations, one should be aware that individuals negotiate on behalf of institutions.
As a result, biases might be present, especially as the decision-makers themselves or
relatives could be affected by the disease for which the pharmaceutical is provided.
From a political perspective, this raises the question of who should be deciding on
pharmaceutical prices (e.g. decision-makers with statutory health insurance, conser-
vatives). From a different perspective, it might be an option to consider taking not
only the pharmaceutical’s benefit (efficacy) but also the characteristics of the phar-
maceutical’s target population into account when defining prices on behalf of them.
6If a manufacturer decides to price its pharmaceutical above the negotiated price, patients have to
pay the difference and therefore co-payment might exceed e10 (DeutschesApothekenPortal (DAP),
2019).
7Besides the anchor effect, we tested for framing effects and present bias (Tversky & Kahneman,
1981; O’Donoghue & Rabin, 1999). However, we find no statistically significant effects.
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However, further research is necessary regarding these two issues.
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Chapter 3
Determinants of Willingness to Pay
for Health in Germany –
A Literature Review*
3.1 Introduction
Healthcare expenditure of the OECD countries is increasing and subject to discussions
regarding an efficient allocation of resources (OECD, 2019b; World Health Organiza-
tion (WHO), 2019). For the allocation, it is interesting to find out about society’s
preferences regarding health.
These preferences, however, are not apparent and to some extent ambiguous (see,
for example, Croson and Gneezy (2009) for gender differences in preferences and
Kahneman and Tversky (1982) for results that show individuals’ decision making to
be not objective, however, following certain patterns).
Ryan et al. (2001) present different quantitative and qualitative methods to reveal
preferences. Among others, the willingness to pay (WTP), which is based in welfare
economics (Pauly, 1995; Samuelson, 1938, 1948).1 Over time, willingness to pay has
become an established method to elicit public preferences in the area of healthcare as
well (O’Brien & Gafni, 1996; Klose, 1999; Smith, 2000).
Nevertheless, the results of willingness to pay studies need to be viewed with
caution. Studies differ regarding their selection from the variety of methods to measure
∗This chapter is based on Lamping (2021).
1Gafni (1998) differentiate between the use of willingness to pay as a measure for individual




willingness to pay (Breidert, Hahsler, & Reutterer, 2006; Diener, O’Brien, & Gafni,
1998). These differences in methodology, however, are found to influence the stated
willingness to pay (c.f. Nimdet, Chaiyakunapruk, Vichansavakul, & Ngorsuraches,
2015 and Ryen & Svensson, 2015, presenting literature reviews on willingness to pay
for a quality adjusted life year). Using the results of willingness to pay studies for
healthcare decision-making becomes, therefore, difficult when the stated preferences
are already affected by the studies’ settings.
Besides methodological approaches, further factors might influence the stated will-
ingness to pay as well. Lamping et al. (2020) find queried subjects’ willingness to pay
for pharmaceuticals to depend on their characteristics (e.g. conservative values, stated
importance of the social security system). Note that decisions regarding pharmaceuti-
cal prices are made by institutions on behalf of the public (Federal Ministry of Health,
2016). In turn, these institutions are represented by individuals whose evaluations of
pharmaceuticals might be affected by their characteristics as well.
The number of papers that condense the findings on the various factors of willing-
ness to pay for healthcare is small and focused on very specific topics. Nosratnejad,
Rashidian, and Dror (2016) (low and middle income countries) and Noor Aizuddin
and Aljunid (2017) conducted literature reviews and present factors of willingness
to pay for health insurance. Noor Aizuddin, Sulong, and Aljunid (2012) review the
existing literature for determinants of willingness to pay for health in general. This
study, however, is only available in the form of an abstract. These studies find the
willingness to pay to be affected by the following factors: income, education, age,
household size and place of residence.
With this work, I want to contribute by presenting factors potentially influencing
people’s (stated) preferences for healthcare in general. This is done by conducting a
literature review.2 Hereby, I focus on Germany, which is no exception regarding the
health expenditure increase (Federal Statistical Office (Destatis), 2020), and where the
evaluation of health enjoys great attention (Henke, 2004; Bundesvernband Deutscher
Internisten, 2008; Balzter, 2018). Moreover, Germany is of particular interest because
of its health insurance system based on solidarity (Federal Ministry of Health, 2015).
A majority (89%) of the German population (Federal Ministry of Health & Association
of Private Health Insurance, 2019) does not bear individual treatment costs directly
but indirectly via income-based contributions to a public health insurance system
2Information regarding the literature search strategy (C.1), the PICO(S) framework, the inclusion
and exclusion criteria (C.2) and the sample selection process (C.3) as well as a list of the reviewed
studies (C.4) can be found in the Appendix.
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(Blümel & Busse, 2019). This makes it difficult to elicit the public’s preferences
regarding healthcare expenditure (cf. Hanley, Ryan, & Wright, 2003).
The reviewed studies in this work contain two categories of determinants: charac-
teristics of the survey participants and methodological approaches in the survey. The
characteristics can be further divided into health and socio-economic characteristics.
Furthermore, three overarching topics of the reviewed studies are identified: disease
treatment, prevention and health insurance.
The relationship between health status and willingness to pay is analysed for all
three of these topics. The healthier the queried subjects, the lower their willingness
to pay for disease treatment and health insurance. No correlation is found for the
topic of prevention. In line with basic economic theory (c.f. Carson, Flores, & Meade,
2001 for use and existence value), the studies find patients suffering from a particular
disease to have higher preferences for treatment, preferably financed via solidarity
health insurance. Also, participants who perceive their risk of a health state decrease
to be higher, and those who had past exposure to a disease are willing to pay a higher
amount for preventing this respective event. Surprisingly, the effect of risk perception
and past exposure on health insurance preferences has not yet been examined. Lastly,
and opposing to economic theory, the health economic literature finds lower prefer-
ences for community funded health insurance among participants conducting harming
habits such as smoking.
Regarding socio-economic characteristics, a positive correlation is found between
income, education and employment, and willingness to pay. Moreover, opting out
of statutory health insurance (having private health insurance) positively affects the
willingness to pay. Regarding gender and age, mixed results are found. However, one
essential common feature is that the effects of these factors lose statistical significance
when controlling for income (gender pay gap) and health (decreasing with age). Will-
ingness to pay seems to be independent of marital status and the number of children.
Interestingly, there is still a difference found between participants living in East and
West Germany.
Besides the participants’ characteristics, the health economic literature finds the
survey methodology to influence the willingness to pay as well. Results show the
willingness to pay to depend on the form of questioning (questionnaire vs interview),
the order of questions and the elicitation method (payment cards vs discrete choice).
Furthermore, questioning participants regarding their general willingness to pay neg-
atively influences the amount they are willing to pay. A similar effect occurs when
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the amount “e0” is given a prominent position among the willingness to pay choices.
On the other hand, emphasising that the participants work on a fictitious scenario
increases the willingness to pay.
The remainder of this paper is structured as follows: potential factors of willingness
to pay and their effect on the willingness to pay in the literature are presented in
section 3.2. Section 3.3 concludes with some general comments.
3.2 Determinants
The purpose of this literature review is to illustrate how individuals’ evaluation of
health-related topics is affected by factors beyond the benefit of a certain intervention.
These factors can be divided into two distinct categories: characteristics of the study
participants and methodological approaches in the surveys. In addition, I distinguish
in the following between health and socio-economic characteristics. The reviewed
studies contain three overarching health-related topics: disease treatment, prevention
and health insurance.
3.2.1 Health characteristics
The analysed studies find the queried subjects’ health status to affect their willingness
to pay. Moreover, the studies present results that show the willingness to pay to
depend on the participants’ perceived personal risk and their past exposure to a
disease. Studies surveying patients and non-patients (healthy subjects, physicians)
find their willingness to pay to differ.
Health status. Studies of all three health-related topics (disease treatment, pre-
vention and health insurance) cover the effect of the participants’ health status on
the willingness to pay. However, an effect is only found for studies analysing the
willingness to pay for disease treatment and health insurance. The willingness to pay
for prevention seems to be uncorrelated with the health status (Himmler, van Exel,
Perry-Duxbury, & Brouwer, 2020 [prevention of infectious diseases]; Mayer et al., 2019
[genetic testing for prostate cancer]; Sikorski et al., 2012 [obsesity prevention]; Siol,
Lange, Prenzler, Neubauer, & Frank, 2017 [oncological genetic testing]).
Regarding disease treatment, results generally show participants with a worse
health state to have a higher willingness to pay. However, the results differ in that
(a) within certain studies, one health measure finds an effect while another does
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not (e.g. Schmitt, Meurer, Klon, & Frick, 2008 [treatment of psoriasis and atopic
eczema]) and (b) the same health state measure used in different studies has only a
correlation with the willingness to pay in some of them (e.g. Beikert, Langenbruch,
Radtke, & Augustin, 2013 [treatment of rosacea] vs. Augustin et al., 2018 [melanoma
treatment]).
Skin diseases are common, and one of the leading causes of disease burden (Seth,
Cheldize, Brown, & Freeman, 2017). While their impact on the quality of life of those
affected is high (e.g. stigmatisation; Audureau, Davis, Besson, Saba, & Ladner, 2019),
the diseases are largely non-fatal (Seidler, Bayoumi, Goldstein, Cruz, & Chen, 2012).
Willingness to pay studies represent an opportunity to quantify the burden of disease
due to skin conditions and are also very prominent in the reviewed health economics
literature.
Schiffner et al. (2003) assess the use of willingness to pay and time trade-off (TTO)
as measures for psoriasis patients’ quality of life (for further information on time-trade-
off, see Dolan, Gudex, Kind, & Williams, 1996). They analyse the changes in these
measures over time and compare them with the participants’ health status. They use
the Psoriasis Disability Index (PDI) and the Psoriasis Area and Severity Index (PASI)
as health state measures and find a statistically significant correlation between the
health status and the willingness to pay.3 With an increasing health status, queried
subjects’ willingness to pay decreases. Similar results are found by Beikert et al.
(2013) [assessing the burden of disease for patients with rosacea], Radtke, Schäfer,
Gajur, Langenbruch, and Augustin (2009) [evaluating the disease burden of vitiligo
patients] and Schmitt et al. (2008) [assessing health utilities of patients suffering from
psoriasis and atopic eczema, and the general population], all using the Dermatology
Life Quality Index (DLQI). Beikert et al. (2014) [assessing patients’ burden of disease
due to atopic dermatitis] also using the DLQI, find only a marginal correlation. Yet,
(Beikert et al., 2013, 2014) find a correlation between the health state measured
using the EuroQol instrument, EQ-5D VAS, and the willingness to pay (for further
information on the EQ-5D, see EuroQol Research Foundation, 2019b). This result
is also found by Radtke et al. (2009) [vitiligo patients]. In contrast, Schmitt et al.
(2008) [psoriasis and atopic eczema patients and general population] present results
that show only a weak relationship between different measures of utility (TTO, VAS,
WTP) and conclude that they are not interchangeable. Moreover, Schmitt et al.
3Schiffner et al. (2003) find a correlation between the changes in PDI, PASI, TTO and the
willingness to pay from pre to post treatment. In the six months follow-up survey, they find this
correlation only for PDI, TTO and willingness to pay.
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(2008) find no correlation between two further measures of the health status and the
participants’ willingness to pay. These measures are the Eczema Area and Severity
Index (EASI) and the Psoriasis Area and Severity Index (PASI).
In line with the missing correlation between the health status (measured using the
EASI and PASI) and the willingness to pay, disease duration, global disease severity,
symptoms and whether the participants are in current treatment seem to have no
effect in the study by Schmitt et al. (2008) [psoriasis and atopic eczema patients and
general population]. In contrast, this relationship between the disease duration and
the willingness to pay is found by Beikert et al. (2013) [rosacea patients] and Radtke et
al. (2009) [vitiligo patients]. However, the results of the two studies are contradictory.
While Beikert et al. (2013) find participants’ willingness to pay to decrease with the
duration of symptoms, Radtke et al. (2009) find a higher willingness to pay with
an increase of time with the disease. These contradictory effects might be due to
two opposing effects. Longer duration of the disease decreases the quality of life
and therefore increases willingness to pay. On the other hand, individuals’ ability to
adapt might cause a decrease in willingness to pay with longer duration of the disease
(Oswald & Powdthavee, 2008).
Besides general health measures, studies find involvement of specific body areas
to increase willingness to pay (Beikert et al., 2013, 2014: facial involvement; Schmitt
et al., 2008: involvement of genital region).
Adjacent to the area of skin conditions, Augustin et al. (2018) study preferences
for the treatment of melanoma, comparing the willingness to pay of patients and
physicians (the patients’ treating derma-oncologists). Their aim ist to assess the
burden (a.o. psychological) of the disease. Regarding the relationship between the
patients’ health state and their willingness to pay, Augustin et al. (2018) find mixed
results. While they find a higher score (worse health) on the anxiety scale (HADS-A),
assessed by the patients, to affect the willingness to pay positively, they find no effect
for the depression scale (HADS-D).4 Furthermore, they find no correlation between
the EQ-5D VAS and the willingness to pay of patients and physicians.
The relationship between health status and willingness to pay is also studied for the
treatment of other diseases such as the treatment of menopause symptoms (Rasch,
Hodek, Runge, & Greiner, 2009) [measure: Menopause Rating Scale (MRS)] and
depression (König, Bernert, & Angermeyer, 2005) [measures: EuroQoL instruments,
time-trade-off, SF-12 questionnaire] with results showing an increase in willingness to
4Hospital Anxiety and Depression Scale (HADS). See also (Sondermann, 2019) for a study on
the negative effect of depression on the response to psoriasis treatment.
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pay with a decrease in health.
Regarding the preferences for health insurance, a similar effect of higher willingness
to pay by participants with a worse health state is found (Bock et al., 20175 [effect of
longitudinal changes in several factors on the willingness to pay for health insurance]
and Leukert-Becker & Zweifel, 2014 [preferences for obtaining the status quo regarding
health insurance services]). Individuals with a relatively lower health state seem
to especially prefer healthcare provision through publicly financed statutory health
insurance funds (Pfarr & Schmid, 2016 [empirical experiment to test the assumption
by Gouveia (1997) that preferences for the extent of statutory health insurance is
affected by a health-income ratio]).
A major difference between the studies presented so far is the degree to which
the study participants are affected. For example, several studies find an effect of the
health measure EQ-5D VAS on patients’ willingness to pay (Beikert et al., 2013, 2014;
Radtke et al., 2009). However, when surveying patients and non-patients, no effect or
only a marginal one is found (Augustin et al., 2018; Schmitt et al., 2008). Explicitly
differentiating between patients and healthy subjects, a correlation between health
status (EQ-5D VAS) and willingness to pay is only found for patients (König et al.,
2005).
Being a patient. In line with basic economic theory of use value (Carson et al.,
2001), several studies find that being a patient, instead of a healthy subject or the
treating physician, affects the willingness to pay positively. This effect is found for
the treatment of i) different diseases (Augustin et al., 2018 [comparing the preferences
of melanoma patients and their treating physicians]; Krammer & Heinzerling, 2014
[analysing the preferences of patients, physicians and healthy controls for melanoma
treatment]; Günther et al., 2007 [assessing the burden of depressive disorders using
the stated preferences of participants with and without depression]; Rasch et al., 2009
[analysing factors influencing preferences of menopause-aged women for treatment])
and ii) health prevention (Kesztyüs et al., 2014; Lauer et al., 2020 [parents’ willing-
ness to pay for the prevention of childhood overweight]). One exception is found by
Braun et al. (2000) who find a lower willingness to pay for treatment in participants
suffering from erectile dysfunction compared to healthy subjects. This result, how-
ever, is not necessarily contradictory. Depending on the form of financing, queried
subjects’ preferences might change. Affected patients were found to prefer financing
5Bock et al. (2017) find only a correlation between the health status and the willingness to pay
for patients with private health insurance.
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in the form of a (solidarity) contribution to health insurance, whereas non-patients
favour direct copayments (Sennhauser & Zweifel, 2009) [preferences of patients and
healthy subjects regarding the coverage of a diabetes pharmaceutical by the health
insurance].
Perceived risk and past exposure. In general, willingness to pay is expected to
depend on the perceived personal exposure (McDaniels, Kamlet, & Fischer, 1992).6
Focussing on the preferences for health in Germany, an effect of the perceived risk
and the past exposure on the willingness to pay is only found for the topic of preven-
tion. For example, the willingness to pay for predictive oncological genetic testing is
found to positively correlate with the participants’ assessment of their personal risk of
getting the disease (Siol et al., 2017). Moreover, having a family member with lethal
prostate cancer caused participants to state a higher preference for genetic testing of
the respective disease (Mayer et al., 2019). Note that participants of this study by
Mayer et al. (2019) are men who have undergone radical prostate surgery. Within
this group of highly affected participants, exposure of a family member even further
increases the willingness to pay for prevention.
No relationship is found when analysing the willingness to pay for disease treat-
ment (Augustin et al., 2018 [melanoma treatment]). Moreover, despite “risk [being]
the fundamental element of insurance” (Ewald, 1991, p. 199), there is no study that
examines the perceived risk as a potential determinant of health insurance preferences
in the German context. Here, in particular, one would expect risk perceptions to affect
the preferences. Whether these preferences are aligned with economic theory is part
of another discussion (c.f. Slovic, Fischhoff, & Lichtenstein, 1982 who find individuals
to insure against relatively high-probability, low-loss events instead of low-probability
high-loss events.). For a thorough discussion of the topic “risk perception” including
the assessment of risk perceptions, see Slovic (2000).
International studies have found another link between past exposure, perceived
risk and willingness to pay, the comorbidity effect. A history of a certain disease
and the associated higher subjective perception of risk increase the preferences for
treatment of the corresponding disease. In contrast, interest in treatment decreases if
someone has been affected by other diseases in the past and perceives their risk to be
relatively higher (DeShazo & Cameron, 2005). A similar effect is found by Eeckhoudt
6This applies in particular for well defined risks. If uncertainty regarding the probability of risks




and Hammitt (2001). They argue that a so called ‘why bother effect’ explains the
decrease in demand for the treatment of a certain disease in the presence of another
disease.
Harming habits. So far, this study found individuals with a worse health state
to show a higher willingness to pay for treatment. This seems to be especially true
for those being net beneficiaries of treatments financed via public health insurance
(Pfarr & Schmid, 2016) [health-income ratio as predictor of preferences for public
health insurance]. Generally, in Germany, healthcare costs are covered by statutory
health insurance, which is financed by income based contributions independent from
the individual health state (Federal Ministry of Health, 2015). Therefore, one would
expect that people who engage in health-damaging habits like smoking show a higher
preference for health insurance financing. The opposite result is found, however.
When confronted with a fictitious scenario without health insurance, smokers stated
a lower willingness to pay for health insurance with the same standards as their current
one (Bock et al., 2017).
3.2.2 Socio-economic characteristics
In this section, I present results from health economic literature regarding the rela-
tionship between socio-economic characteristics and the willingness to pay for health-
related topics in Germany. Income, education, employment, type of health insurance
coverage, age, gender and region of residence are found to affect willingness to pay in
these studies.
Income, education and employment. The upper boundary of individuals’ will-
ingness to pay is generally defined by their disposable income. Therefore, income is
expected to correlate positively with the willingness to pay (Carson et al., 2001). Nev-
ertheless, Flores and Carson (1997) argue that while a person with a higher income
might buy a higher quantity of a product, the person might not necessarily be willing
to pay a higher amount for the same product than others. For a detailed discus-
sion regarding the relationship between income and willingness to pay, see Flores and
Carson (1997); Hanemann (1991); Horowitz and McConnell (2003); Sugden (2001).
Health economic literature regularly includes income as an explanatory variable
in their willingness to pay analyses. The reviewed studies in this work present results
that show a positive correlation between income and the willingness to pay for dis-
ease treatment, prevention and health insurance in Germany (e.g. Augustin et al.,
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2018 [melanoma treatment]; Schmitt et al., 2008 [treatment of skin conditions]; Mayer
et al., 2019 [genetic testing for prostate cancer]; Kesztyüs et al., 2014 and Lauer et
al., 2020 [prevention of childhood overweight and obesity]; Bock et al., 2016 [prefer-
ences for health insurance]). Regarding preferences for health insurance, Pfarr and
Schmid (2016) analyse the effect of the health income ratio on the willingness to pay
for health insurance.7 Studying participants’ interest in redistribution of resources
towards social public health insurance, they find net beneficiaries (relatively lower
income or relatively lower health) to be in favour of an allocation towards the ones in
need. Moreover, these participants also state higher preferences for an extension of
healthcare resources.
Nevertheless, this review also contains studies which find no correlation between
income and willingness to pay. For the topic of prevention, this is only one study
that also exclusively surveys students. Furthermore, the participants of this study
show at least a higher general willingness to pay if they assess their financial situation
to be above the group’s average (Siol et al., 2017 [preferences for oncological genetic
testing]). However, there are also studies where the reason for the missing relationship
is not apparent (e.g. Beikert et al., 2013 and Schiffner et al., 2003 [treatment of skin
conditions]; Bock et al., 2017 [longitudinal study on factors of willingness to pay for
health insurance]; Krammer & Heinzerling, 2014 [melanoma treatment]).
Besides income, there is a positive relationship between education and employment
status, and the willingness to pay for healthcare found in the literature. However,
controlling for income causes them to lose their statistical significance, potentially
due to their interrelationship (e.g. Augustin et al., 2018). Nevertheless, the positive
effect of education and employment on the willingness to pay remains statistically
significant in some cases, even when controlling for income (education: Mayer et al.,
2019 [genetic testing for prostate cancer] and Bock et al., 2016 [preferences for health
insurance]; employment: Himmler et al., 2020 [prevention of infectious diseases]).
Statutory health insurance. In principle, having statutory health insurance is oblig-
atory in Germany. Under certain circumstances exempting from compulsory insurance
and taking out private insurance is possible. One major reason is exceeding a certain
income limit (Federal Ministry of Health, 2020). Correlation between income and
insurance coverage and, therefore, mitigation of the effect of the insurance type on
the willingness to pay is assumed. Against ecxpectation, being insured with statutory




health insurance reduces the willingness to pay for healthcare even when controlling
for income (Ahlert, Breyer, & Schwettmann, 2016 [differences in stated preferences for
a QALY due to survey techniques; further details in section 3.2.3]; Bock et al., 2016
[factors of willingness to pay for health insurance]). One explanation for the differ-
ence might be the higher price consciousness of people with private health insurance.
While medical services are paid for directly by the statutory health insurance, those
with private insurance pay the bill first and then receive the money back from their
insurance company (Sueddeutsche Zeitung, 2016).
For the studies not finding a relationship between the type of health insurance and
willingness to pay it is noticeable that these have either a specific topic or a specific
participant group. Köberlein and Klingenberger (2011) examine the willingness to pay
for dental procedures. The proportion of services paid for privately by patients is much
higher for dental procedures than for all other specialities (Balzter, 2019). Therefore, a
relatively greater price consciousness of statutorily insured persons is assumed for this
medical discipline. Siol et al. (2017) examine the preferences for oncological genetic
testing. Participants are students who are either insured by law through their parents
or, in rare cases, as children of civil servants privately insured. In both cases, financing
runs through their parents. Furthermore, it can be assumed that students generally
have a lower awareness of illness due to their age. Unfortunately, none of the reviewed
studies tested cost awareness, income and health insurance coverage simultaneously.
Age. In the existing health economic literature, several studies examine the effect
of age on willingness to pay. In principle, it can be assumed that health declines with
increasing age. Income is expected to increase with age and then to decrease with
retirement. In line with these assumptions, studies find the correlation between age
and willingness to pay to disappear once they control for income and health status
(Augustin et al., 2018 [melanoma treatment]; Schmitt et al., 2008 [treatment of skin
conditions]). Consistent with the conjecture that the correlation between income and
age is concave shaped, the highest willingness to pay is found for participants aged
25-50 years in comparison to younger and older participants (Schmitt et al., 2008
[treatment of skin conditions]). Controlling only for the health state, Sikorski et
al. (2012) (obesity prevention) and Günther et al. (2007) (treatment of depression)
find willingness to pay to increase with age. Few studies present results that show
the willingness to pay to depend on the queried subjects’ age despite controlling for
health and income. However, these studies have special characteristics. Leukert-
Becker and Zweifel (2014) find a positive effect of age on the willingness to pay for
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health insurance. To be precise, older participants and especially retirees, show a
higher preference for maintaining the status quo in terms of their health insurance
services. A second study examines factors influencing the adoption of mobile health
apps. Willingness to pay for these apps decreases with age (Lupiáñez-Villanueva,
Folkvord, & Vanden Abeele, 2020).
Gender. Assuming an effect of income on willingness to pay, it stands to reason
that a large share of the relationship between gender and willingness to pay is due
to the gender pay gap (Blau & Kahn, 1999; Graf, Brown, & Patten, 2018). Several
studies indeed find no effect of gender when controlling for income (e.g. Augustin
et al., 2018 [melanoma treatment]; Schmitt et al., 2008 [skin condition treatment];
Siol et al., 2017 [oncological genetic testing]; Leukert-Becker & Zweifel, 2014; Pfarr &
Schmid, 2016 [preferences for health insurance]). However, health economic literature
also presents results that show men’s willingness to pay for health to be higher even
when controlling for income (Hammerschmidt, Zeitler, & Leidl, 2003 [comparison of
the results of discrete choice experiments and payment cards conducted with diabetic
patients]; Himmler et al., 2020 [warning system for infectious diseases]; Bock et al.,
2016 [preferences for health insurance]). These results are in line with more general
findings regarding the willingness to pay for public goods (Brown-Kruse & Hummels,
1993). Moreover, differentiating between the stated amount of willingness to pay
and the general willingness to pay, the former is found to be higher for men while
women seem to have a higher general willingness to pay (Ahlert et al., 2016 [effect
of survey methods; see section 3.2.3]). Note that all of the mentioned studies use
only fictitious scenarios when conducting their willingness to pay surveys. Brown and
Taylor (2000) present results that show gender-specific differences to appear only in
fictitious scenarios. In experiments where participants actually carry out a positive
willingness to pay, they find no difference.
Marital status, children, single parenthood, household size. With whom people live
seems to have only little influence on their willingness to pay for health. Preferences
are found to be independent of the marital status, the number of children (Krammer
& Heinzerling, 2014 [melanoma treatment]; Mayer et al., 2019 and Siol et al., 2017
[oncological genetic testing]), and whether participants are single parents (Lauer et
al., 2020 [prevention of childhood overweight]). Regarding the household size, two
studies find it to affect the willingness to pay. Hammerschmidt et al. (2003) [diabetes
treatment] find a lower willingness to pay in patients who live in bigger households.
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Augustin et al. (2018) [melanoma treatment] present results that show physicians
living alone to have a lower willingness to pay.
East Germany. The reunification between East Germany (former German Demo-
cratic Republic) and West Germany took place in 1990. Since then, differences be-
tween the two populations have been studied by a wide range of disciplines (Connolly,
2020). These studies show for example that “East Germans are more in favour of re-
distribution and state intervention than West Germans” (Alesina & Schuendeln, 2005,
p. 1508). However, this is found to be especially true for older people who lived under
communism and conversion is predicted (Alesina & Schuendeln, 2005). Several recent
studies find no difference between the two populations regarding the evaluation of
healthcare (Köberlein & Klingenberger, 2011 [dental treatment]; Leukert-Becker &
Zweifel, 2014 [preferences for health insurance services]; Pfarr & Schmid, 2016 [re-
distribution through health insurance]; Sikorski et al., 2012 [prevention of obesity]).
Caution is warranted for those studies that do find a relationship but do not control
for income differences between East and West Germany (e.g. Schomerus, Angermeyer,
Matschinger, & Riedel-Heller, 2008 [prevention of depression]; see Statistical Offices
of the Federal and State Governments, 2020 and Federal Statistical Office of Ger-
many, 2020 for income differences between East and West Germany). Nevertheless,
one study controlling for the effect of income finds people living in East Germany to
have a lower willingness to pay (for a QALY) (Ahlert et al., 2016) [effect of survey
methods].
3.2.3 Survey methods
So far, I have referred to the influence of individuals’ characteristics on the willing-
ness to pay in the health economic literature. Health state, having a certain disease,
risk perception, harming habits, income, education, employment, type of health in-
surance coverage, age, gender, and even place of residence are found to influence the
willingness to pay for healthcare. To be precise, they affect the stated willingness to
pay in surveys. Studies, however, differ regarding their survey methods. They use
various survey forms (questionnaire, interview), elicitation methods (payment cards,
discrete choice), payment forms (insurance premium, out-of-pocket) and payment fre-
quencies. Moreover, the treatment effects presented in the respective studies differ
(health improvement, life extension). In the prominent area of willingness to pay for
a quality adjusted life year, several studies have already found a correlation between
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the survey methodology and the stated willingness to pay (see Nimdet et al., 2015 for
a comprehensive review.) In the German healthcare context, similar effects are found
as well. In the following, these effects are presented.
Elicitation method. Using contingent valuation to elicit individuals’ preferences,
there are two prominent ways to disclose willingness to pay: discrete choice and
payment cards (Diener et al., 1998). Results are found to differ between these two
methods (c.f. Hammerschmidt et al., 2003, examining the convergent validity of the
two methods, finding unanticipated yes/no responses). However, it must be taken
into account that Hammerschmidt et al. (2003) also use different forms of data col-
lection. Payment cards are used in face-to-face interviews, while a questionnaire is
used to conduct the discrete choice experiment. It is precisely this difference between
the survey forms that potentially affects results as well. A personal interviewer, for
example, is found to increase the willingness to pay (Ahlert et al., 2016).
Effect of the treatment. More precisely, Ahlert et al. (2016) examine the willingness
to pay for a quality adjusted life year. Hereby they distinguish between measures that
extend life expectancy and those that improve health. Their results show a higher
number of positive willingness to pay statements for the improvement of the quality
of life then for a life extension. However, when analysing only the positive statements,
they find queried subjects to prefer life extension.
Present preference. Moreover, Ahlert et al. (2016) find participants to prefer im-
mediate health gains. Queried subjects were less willing to pay any positive amount
of money for a health gain at the end of their life than for a health gain in one year.
In fact, results show, the more immediate the health gain, the higher the willingness
to pay. This result is consistent with the basic expectation that a health gain at an
earlier stage is considered more valuable. The National Institute for Health and Care
Excellence’s (NICE) official recommendation is to discount QALYs at 3.5% per year
(Whitehead & Ali, 2010). Whether the participants’ evaluation in the study by Ahlert
et al. (2016) is time-consistent cannot be answered here.8
Payment frequency. Note that the necessary payment for the treatment in the
study by Ahlert et al. (2016) is basically immediate in the form of a single amount.
In a deviating scenario, they test the effect of an instalment payment over four years.
This causes participants to state a twice as high total amount which they are willing
8See O’Donoghue and Rabin (1999) analysing present biased preferences.
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to pay. A similar result for participants from Denmark is found by Gyrd-Hansen,
Jensen, and Kjaer (2014), who find the willingness to pay to be higher if stated in the
form of a monthly payment than a yearly one.
Hypothetical scenario. The phenomenon of stated preferences differing from ac-
tual behaviour is known as the hypothetical bias (c.f. Fifer, Rose, & Greaves, 2014;
Hensher, 2010). In the case of preferences for healthcare in Germany, emphasising
that the queried subjects are in a hypothetical scenario without health insurance and
therefore need to pay for the intervention themselves increases the queried subjects’
willingness to pay (Ahlert et al., 2016). Methods to reduce this hypothetical bias can
be found at Blumenschein, Blomquist, Johannesson, Horn, and Freeman (2008).
General willingness to pay. Several of the reviewed studies ask participants not
only for the amount they are willing to pay but also for their general willingness to
pay. Liebe et al. (2011), analysing the willingness to pay for public environmental
goods, distinguish between the in-principle willingness to pay and the stated amount
of willingness to pay. Their results show that income has an influence on the amount
of willingness to pay while the general decision for or against payment is independent
of income. A comparison of the differences between general willingness to pay and
the amount of willingness to pay can be found at Cragg (1971).
Regarding the preferences for healthcare, asking participants for their general will-
ingness to pay (binary yes/no filter) before eliciting the amount of money they are
willing to pay is found to increase the zero responses (Ahlert et al., 2016). The rea-
son for this result is seen by Ahlert et al. (2016) in the increased prominence of the
response option e0. Therefore, Ahlert et al. (2016) and Gyrd-Hansen et al. (2014)
[Denmark] are of the opinion that a binary filter biases results and should be avoided.
In my opinion, another interpretation is also conceivable. The binary filter (general
willingness to pay) might act as a kind of hurdle. This hurdle makes the participants
question the default option of using the treatment and consequently also paying for
it. Instead, queried subjects start to decide consciously for or against the treatment
and state their willingness to pay accordingly. See Thaler and Sunstein (2003) for
information on the “status quo bias” to use the default setting.
For the studies reviewed in this paper, it is striking that except for the study
by Ahlert et al. (2016), only studies on the topic of prevention ask participants for
their general willingness to pay. For this topic, the general willingness to pay is even
regularly queried (e.g. Kesztyüs et al., 2014, Lauer et al., 2020 and Sikorski et al.,
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2012 [obesity prevention]; Schomerus et al., 2008 [prevention of depression]; Mayer et
al., 2019 and Siol et al., 2017 [oncological genetic testing]).
Survey structure. The health economic literature presents results that show the
willingness to pay to depend on survey methods such as the elicitation method, the
presented scenario, the frequency of payment, and the existence of a question regarding
the general willingness to pay. Moreover, the willingness to pay is found to be even
affected by the position of questions within the survey as well as the order of the
monetary willingness to pay options itself (Ahlert et al., 2016).
Summing up, the health economic literature presents results that show the willing-
ness to pay for healthcare in Germany to be affected by factors besides the treatment’s
benefit. These factors are the individuals’ health and socio-economic characteristics
as well as the survey methods used. Table 8 provides an overview of the determinants,




health status disease treatment Augustin et al. (2018); Beikert et al. (2013, 2014); Ham-
merschmidt et al. (2003); König et al. (2005); Radtke et al.
(2009); Rasch et al. (2009); Schiffner et al. (2003); Schmitt
et al. (2008)
health insurance Bock et al. (2017); Leukert-Becker and Zweifel (2014);
Pfarr and Schmid (2016)
being a patient disease treatment Augustin et al. (2018); Braun et al. (2000); Krammer and
Heinzerling (2014); Günther et al. (2007); Rasch et al.
(2009)
prevention Kesztyüs et al. (2014); Lauer et al. (2020)
health insurance Sennhauser and Zweifel (2009)
risk and exposure prevention Mayer et al. (2019); Siol et al. (2017)
harming habits health insurance Bock et al. (2017)
income disease treatment Augustin et al. (2018); Schmitt et al. (2008)
prevention Kesztyüs et al. (2014); Lauer et al. (2020); Mayer et al.
(2019)
health insurance Bock et al. (2016); Pfarr and Schmid (2016)
education prevention Mayer et al. (2019)
health insurance Bock et al. (2016)
employment prevention Himmler et al. (2020)
insurance coverage disease treatment Ahlert et al. (2016)
health insurance Bock et al. (2016)
age disease treatment Lupiáñez-Villanueva et al. (2020)
health insurance Leukert-Becker and Zweifel (2014)
gender disease treatment Ahlert et al. (2016); Hammerschmidt et al. (2003)
prevention Himmler et al. (2020)
health insurance Bock et al. (2016)
household size disease treatment Augustin et al. (2018); Hammerschmidt et al. (2003)
east Germany disease treatment Ahlert et al. (2016)
elicitation method disease treatment Ahlert et al. (2016); Hammerschmidt et al. (2003)
health improvement or life
extension
disease treatment Ahlert et al. (2016)
present preference disease treatment Ahlert et al. (2016)
payment frequency disease treatment Ahlert et al. (2016)
hypothetical scenario disease treatment Ahlert et al. (2016)
general willingness to pay disease treatment Ahlert et al. (2016)
survey structure disease treatment Ahlert et al. (2016)
Table 8: Determinants of willingness to pay for healthcare in Germany. Only those
determinants are mentioned where a relationship to the willingness to pay is found.
The effect of the variables education, employment, insurance coverage, age and gender





A large number of studies investigate the respective willingness to pay and its fac-
tors for very different topics in the field of healthcare. Very few studies, however,
summarise these factors, and they do so only for very specific topics. This paper,
therefore, has addressed the question which factors influence individuals’ evaluation
of healthcare in general. The focus here was placed on the German context. Based
on a review of findings in health economics, I have in particular emphasised the dis-
tinction between two types of determinants; characteristics of the participants and
methodology of the survey. Characteristics were further divided into two classes:
health and socio-economic.
In principle, the results of the individual studies agree on the effects and their
direction. Willingness to pay increases as health declines. This is especially the case
if the respondents actually suffer from the corresponding disease. The perception of
the own risk and exposure correlates positively with the willingness to pay. Harming
habits (e.g. smoking), on the other hand, reduce the willingness to pay for health-
care. Furthermore, income, education and employment have the expected positive
effect. Being insured by statutory health insurance and living in East Germany (both
controlled for income) are found to have a negative impact on the willingness to pay.
Queried subjects’ age, gender and the size of their household seem to affect their
willingness to pay. However, the effect direction differs between the studies.
Interestingly, some determinants are not examined at all for certain topics (e.g.
effect of risk perception on willingness to pay for health insurance). Moreover, it is
striking that determinants for which an effect is found in principle do not seem to
have any influence in several studies of a certain topic (e.g. no correlation is found
between health status and willingness to pay for the topic of prevention while this
effect is found several times for the other two topics.)
General findings regarding the influence of study methodology on participants’
stated preferences are also confirmed for the German healthcare context. Survey
form (questionnaire, interview), elicitation method (discrete choice, payment cards),
presented scenario (health improvement, life extension) and emphasis on its hypothet-
ical nature, a question regarding the general willingness to pay and even the question
order are found to affect the queried subjects’ willingness to pay. Regarding the re-
sults of this review, isolated effect deviations for some determinants in certain studies
might be explained by this influence of the survey methodology.
The health economic literature (German context) analyses a variety of determi-
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nants of willingness to pay. However, they are all essentially covered by models from
basic economic theory (e.g. disposable income as upper boundary of willingness to
pay; higher use value of patients compared to non-patients’ existence value). Further
potential determinants are provided by psychological and sociological theories (c.f.
Liebe et al., 2011). These are, for example, trust in the cooperation and fairness of
others (theory of public goods: Kollock, 1998; Ostrom, 2000; Fehr & Schmidt, 1999)
and awareness of need and responsibility (norm-activation model: Schwartz, 1977;
Schwartz & Howard, 1982). For more details, see Table C.5 in the Appendix.
The conclusion from the results of this study is twofold. If one wants to take
the peoples’ preferences into account for decisions on resource allocation, the elicited
preferences from multiple willingness to pay studies should be considered. For this,
standardisation regarding the variables controlled for in these studies is necessary.
This review presents a first overview of potential determinants. From a different
perspective, considering the characteristics of a respective target group for which a
decision is made might be an option.
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In the essays presented in this thesis, I analysed determinants potentially affecting the
evaluation of healthcare in Germany. The first study deals with the pricing process of
pharmaceuticals. These prices defined on an institutional level seem to depend only to
a small extent on the benefit of the respective pharmaceutical. Therefore, there must
be factors besides the actual benefit of the drug that influence the evaluation. Price
negotiations are conducted by individuals on behalf of institutions. It is very likely
that the decisions of these individuals are influenced by a wide variety of personal
factors (c.f. Katona, 1975). I was interested in finding out what variables influence
people’s evaluation of pharmaceuticals. Indeed, preferences stated by participants of
a willingness to pay survey depended not only on their perception of the pharmaceuti-
cal’s benefit. Their characteristics (e.g. conservative values) affected their willingness
to pay as well.
The first two studies focussed on the evaluation of pharmaceuticals. In a third
study, I analysed the preferences for healthcare in general, conducting a literature
review. In line with the previous results, the health economic literature finds the
willingness to pay to depend on several factors besides the treatment’s actual benefit.
These factors can be assigned to two categories: Characteristics of the study partici-
pants and methodology of the study. The characteristics studied in the literature are
mainly health (e.g. health status, being a patient) and socio-economic (e.g. income,
age) characteristics.
In the context of this work, I have shown that the (perceived) benefit of a treatment
is only one of the determinants that influence individual evaluation. However, the
determinants studied are essentially rooted in economics. Other disciplines such as
psychology and sociology offer theories from which further potential factors regarding
healthcare preferences could be derived.
To conclude, with regard to drug price negotiations, it would certainly make sense
to adapt the processes so that the influence of the representatives’ characteristics on
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the negotiation outcome is reduced. Also, a standardisation of preference studies
(willingness to pay) would probably make them more usable as a basis for healthcare
decisions. Nevertheless, I believe that the fundamental question is different. Should
healthcare be evaluated solely on the basis of its effectiveness? Or should, for example,
the preferences of the target group of a particular treatment be taken into account
when making decisions on their behalf. With the work presented in this thesis, I hope
I have contributed to this topic and potential future discussions.
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In addition to the main analysis, we conducted seven sensitivity analyses clustered
into four different groups. Further information regarding the groups can be found
below. The results of the sensitivity analyses (M7-M13) are provided in Table A.1.2.
For all models, there is no change in the main results compared to our final model
M6 presented in the main body of the text. In M12, however, the variable measuring
the extent of the additional benefit becomes statistically insignificant. This only
strengthens the point made in the paper.
Group 1: Three additional versions of the point score for the extent of the addi-
tional benefit (see Table A.1.1 & Table A.1.2) were analysed in models M7 to M9.
extent benefit / point score M6 M7 M8 M9
major 6 6 6 6
considerable 5 5 4 5
minor 3 4 3 2
non quantifiable 4 3 5 4
no added benefit 2 2 2 1
lesser benefit 1 1 1 0
Table A.1.1: Sensitivity analyses. Transformation of the extent of the additional
benefit into different point scores for each model.
Group 2: Two analyses using dummy variables were conducted (see Table A.1.2).
M10 uses a binary variable for the existence of a weighted additional benefit (extent
and certainty) while M11 tests whether the indication / patient group has an addi-
tional benefit (extent / certainty) which is weighted by the population size afterwards.
A point score at and above 0.5 is defined as an added benefit.
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A.1. Sensitivity Analyses
Group 3: M12 (see Table A.1.2) displays the results of using data of the patient
group with the highest extent of the additional benefit granted by the Federal Joint
Committee for the corresponding EBA.
Group 4: Here we consider a model without outliers, excluding 8 EBAs with a
Cook’s that exceeds the threshold of 4/n from M6 in a separate sensitivity analysis












premium M6 M7 M8 M9 M10 M11 M12 M13
launch 0.960∗∗∗ 0.958∗∗∗ 0.958∗∗∗ 0.959∗∗∗ 0.960∗∗∗ 0.962∗∗∗ 0.967∗∗∗
extent additional benefit 0.172∗ 0.146∗
extent additional benefit M7 0.167∗∗
extent additional benefit M8 0.184∗
extent additional benefit M9 0.142∗
additional benefit per EBA (yes / no) 0.090∗
additional benefit patient group (yes / no) 0.084∗
certainty additional benefit 0.151 0.131 0.172 0.079 0.202∗
extent * certainty -0.058 -0.061∗
extent * certainty M7 -0.052
extent * certainty M8 -0.064
extent * certainty M9 -0.047∗
launch high 0.984∗∗∗
extent high (additional benefit) 0.062
certainty high (additional benefit) 0.043
extent high * certainty high -0.012
renegotiation 0.224∗∗∗ 0.226∗∗∗ 0.221∗∗∗ 0.219∗∗∗ 0.226∗∗∗ 0.228∗∗∗ 0.218∗∗∗ 0.213∗∗∗
arbitration -0.120∗∗ -0.124∗∗ -0.120∗∗ -0.125∗∗ -0.114∗∗ -0.114∗∗ -0.128∗∗ -0.112∗∗
constant -0.690∗∗∗ -0.674∗∗∗ -0.719∗∗∗ -0.482∗∗∗ -0.305∗∗∗ -0.301∗∗∗ -0.472∗∗∗ -0.660∗∗∗
N 187 187 187 187 187 187 183 178
R-sqr 0.948 0.948 0.948 0.948 0.947 0.947 0.964 0.968
Table A.1.2: Sensitivity analyses. Comparison of M6 (final model) to seven sensitivity analyses models;
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.66
A.2. Renegotiation
A.2 Renegotiation
In order to test in how far renegotiations influence our results, we excluded all 69
renegotiated EBAs leaving 118 EBAs eligible for analysis. Again, all main results
remain unchanged; cf. Table A.2.
premium M6 M14
launch 0.960∗∗∗ 0.970∗∗∗
extent (additional benefit) 0.172∗ 0.230∗
certainty (additional benefit) 0.151 0.257






Table A.2: Comparison of M6 (final model) to M14 (excluding renegotiated EBAs);




We conduct an ordered probit regression, treating the independent variables as interval
scaled (willingness to pay: M5; added benefit: M7). Moreover, we use dichotomous
independent variables (one if item on six-point Likert-scale is greater than three, zero




willingness to pay willingness to pay willingness to pay
b/se b/se b/se
lung cancer reference reference reference
psoriasis -76.487∗∗∗ -0.092 0.070
(21.11) (0.10) (0.09)
heart failure -2.989 0.198∗ 0.227∗
(20.09) (0.09) (0.09)
copd -61.424∗∗ -0.076 -0.072
(20.23) (0.09) (0.09)
fictitious price reference reference reference
no price information -83.966∗∗∗ -0.298∗∗∗ -0.299∗∗∗
(17.28) (0.08) (0.08)
real price -55.749∗∗ -0.177∗ -0.178∗
(17.30) (0.08) (0.08)
added benefit 20.028∗∗∗ 0.215∗∗∗ 0.915∗∗∗
(3.67) (0.02) (0.08)
statutory health insurance -68.499∗∗ -0.311∗∗ -0.326∗∗
(23.08) (0.11) (0.11)
conservative 5.020∗∗ 0.006 0.144∗
(1.70) (0.01) (0.07)
consume 7.705∗∗ 0.028∗ 0.047
(2.93) (0.01) (0.04)
social security -14.957∗ -0.081∗∗ -0.208∗
(6.28) (0.03) (0.10)
system confidence 6.884 0.051∗∗ 0.361∗∗
(4.22) (0.02) (0.13)
female -25.844 -0.082 -0.108
(14.84) (0.07) (0.07)
constant -16.153 n/a n/a
(64.95) n/a n/a
N 1032 1032 1032
M1: Linear regression; interval scaled explanatory variables.
M5: Ordered probit regression; interval scaled explanatory variables.
M6: Ordered probit regression; dichotomous explanatory variables.
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001




added benefit added benefit added benefit
b/se b/se b/se
lung cancer reference reference reference
psoriasis 1.879∗∗∗ 1.044∗∗∗ 1.034∗∗∗
(0.16) (0.09) (0.09)
heart failure 0.506∗∗ 0.254∗∗ 0.252∗∗
(0.16) (0.09) (0.09)
copd 0.219 0.106 0.094
(0.16) (0.09) (0.09)
system confidence 0.114∗∗∗ 0.062∗∗∗ 0.262∗
(0.03) (0.02) (0.11)
social security 0.230∗∗∗ 0.120∗∗∗ 0.292∗∗
(0.05) (0.03) (0.09)
female -0.262∗ -0.142∗ -0.143∗
(0.12) (0.06) (0.06)
constant 3.987∗∗∗ n/a n/a
(0.38) n/a n/a
N 1032 1032 1032
M4: Linear regression; interval scaled explanatory variables.
M7 Ordered probit regression; interval scaled explanatory variables.
M8: Ordered probit regression; dichotomous explanatory variables.
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001





Considering only those subjects recommending the pharmaceutical leads to a selection
bias. A two-step Heckman correction is conducted to control for this (Model M7).
(M1) (M7)
willingness to pay conditional willingness to pay
b/se b/se
lung cancer reference reference
psoriasis -76.487∗∗∗ -116.190∗∗∗
(21.11) (26.96)




fictitious price reference reference
no price information -83.966∗∗∗ -117.552∗∗∗
(17.28) (21.26)
real price -55.749∗∗ -76.794∗∗∗
(17.30) (21.10)
added benefit 20.028∗∗∗ n/a
(3.67) n/a






social security -14.957∗ -16.048∗
(6.28) (7.93)












M1: Willingness to pay is assumed to be zero for participants not recommending the new pharmaceutical.
M7: Heckman two-step correction to control for selection bias. Only participants who recommend the new
pharmaceutical are able to state a willingness to pay. The selection model is controlled for the four
different indications.
∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001




The study was conducted on German participants. Therefore the original question-
naire is in German. In order to make it accessible to a broader audience, we have
translated it into English. Small changes in the questionnaire lead to twelve different
treatments (four different diseases and for each disease three different kinds of price
information). As an example, treatment 2 (disease: psoriasis; price information: real













����� �������������� ������ ����� ���� ������� ��� ����
������������������
�
���� ������� ��� ����� ��� �� ����������� ��� �������



































































���� ���� ������������������������� ������� ���������������
������������������������������������������������������������ ����������������
����������������� �



















� � � ����� ����������
�����������
�� �� �� �� �� �� ��









�� ������������������ ��� ���� ���� ����
�� ����������������������� ���� ���� ���� ���� ���� ����
�� ����� ����� ������� ��� �������� ����
���������������
���� ���� ����
�� ������������������ ���� ���� ����
�
���������������������������������� ��������������������� �������
������������������������ � � ���������������������
�� �� �� �� �� ��
�� �� �� �� �� ��
�






�� ���������������������������� ���� ���� ����
�� ����������������������� ���� ���� ���� ���� ���� ����
�� �������������������� ���� ���� ����
�� ��������������������� ���� ���� ���� ����
�� ���������������������� ���� ���� ����
�� ��������������� ���������������������� ���� ���� ���� ���� ���� ����
�� ������������ ���� ���� ����




����������� ��������������������������������������������������������������� ����������������� �����
������������������������������ ��������������� �����������������
����� ���������������� � � �����������������
�� �� �� �� �� ��
















































����� �������� � � ������ ��������
�� �� �� �� �� ��










�� �������� ���� ���� ����




�� �� �� �� �� ��
















������������������� ������������������� ������ ��
����������������������� ������������������� ������ ��
������� ����������������� ������������������� ������ ��
����������������������� ������������������� ������ ��




































•� ���� ������������������������������ �������



























































��������� ������������� ������������������ ������
�
���� ���������������������������������������������
��������������������� � � � �������������������
�� �� �� �� �� �� �� �� �� ��
�� �� �� �� �� �� ��
�



























































































A literature survey was conducted in May and June 2020. I searched for literature
in the following two databases: LIVIVO (2020) and PubMed (2020). Further infor-
mation regarding the search strategy (C.1), the PICO(S) framework, the inclusion
and exclusion criteria (C.2) and the sample selection process (C.3) and the reviewed
studies (C.4) can be found below.
C.1 Search strategy
The database search for studies on willingness to pay for health in Germany was
conducted with an explicit search term using boolean operators (Bramer, De Jonge,
Rethlefsen, Mast, & Kleijnen, 2018). The search term can be found in Figure C.1.
((willingness to pay) OR (willingness to copay) OR (willingness to co-pay))
AND germany AND (pharmaceutical OR pharmaceuticals OR medicine OR
medicines OR drug OR drugs OR health OR healthcare OR (health care) OR
treatment OR treatments OR surgery OR surgeries OR surgical) AND (survey
OR questionnaire OR questionary OR study OR (contingent valuation) OR
(discrete choice))
Figure C.1: Search term using boolean operators.
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C.2. PICO(S) framework, inclusion and exclusion criteria
C.2 PICO(S) framework, inclusion and exclusion
criteria
A PICO(S) framework was defined (see Miller & Forrest, 2001 and Scells et al., 2017).
Inclusion and exclusion were derived from it. The PICO(S) framework and the criteria
can be found in Figure C.2 below.
Articles analysing  
determinants of  
willingness to pay for 
health in Germany
Evaluation of  
willingness to pay 
in patients or  
healthy volunteers
Willingness to  
pay in currency 
converted into  
euro




Population Intervention Comparator Outcome Study Type
Criteria
Inclusion criteria
• Studies which include Germany as study site
• All available scientific articles in the following 
databases: LIVIVO, PubMed
• Studies about willingness to pay
• Health care sector scenario
• Willingness to pay estimation
• Studies with only a part of the population at 
German study site if separate data and evalua-
tion results available
• Scientific article
• Language of the article: English and German
Exclusion criteria
• No determinants for willingness to pay analysed 
in the article
• Other than scientific article (book, thesis/ 
dissertation, conference proceeding)
• Language other than English or German
• No full text version available (e.g. only abstract)
• No statistical analysis (regression analysis) 
regarding determinants of willingness to pay
P I C O S
Figure C.2: PICO(S) Framework to define the systematic literature search strategy.
Inclusion and Exclusion Criteria to define which prospective studies are to be included




Searching the databases with the pre-defined search term (see Figure C.1) caused 196
hits on LIVIVO and 228 hits on PubMed including duplicates within each database
and within all search hits of both sources. Excluding duplicates per database led to 173
hits (23 duplicates) on LIVIVO and 226 hits (2 duplicates) on PubMed. Matching
both databases led to 297 unique studies. After full-text review of these studies
using the pre-defined PICO(S) framework, and inclusion and exclusion criteria (see
Appendix C.2), a total amount of 36 articles considered in this survey. An overview
of the sample selection process can be found in Figure C.3 below. A list of the 36
studies can be found in Table C.4.
Studies identified through database search (n=424)
LIVIVO: (n=196); PubMed: (n=228)
Deletion of duplicates within each database
LIVIVO (n=23); PubMed (n=2)
Unique studies per database
LIVIVO (n=173); PubMed (n=226)
Deletion of duplicates within both databases (n=102)
Unique studies (n=297)
Deletion due to full-text review using the pre-defined PICO(S)
framework, and inclusion and exclusion criteria (n=261)
Review Studies (n=36)
Figure C.3: Study selection. Number of excluded studies in rectangle boxes. Number
of remaining studies in round ellipses boxes. PICO(S) framework, and inclusion and




An overview of the author, content and medical discipline of the 36 reviewed studies
can be found below. Conducting the literature survey we followed the Preferred




Adam et al., 2019 analyse patients’ preferences regarding the treatment




Ahlert et al., 2016 examine differences in stated preferences for life exten-
sion and health improvement due to survey techniques.
not specified
Augustin et al., 2018 use low-risk melanoma patients’ willingness to pay to
assess their burden of disease and compare it with the
willingness to pay of their treating physicians.
oncology
Aumann, Treskova,
Hagemann, & von der
Schulenburg, 2016
analyse determinants of willingness to use and willing-
ness to pay for smoking cessation aids to contribute to
the development of smoking cessation strategies.
pulmonology
Beikert et al., 2013 test the validity of willingness to pay to assess the bur-
den of disease for patients with rosacea.
dermatology
Beikert et al., 2014 assess patients’ burden of disease due to atopic dermati-
tis using willingness to pay and quality of life.
dermatology
Bishai, Brice, Girod,
Saleh, & Ehreth, 2007
analyse the effect of price, benefit and information on
parents’ willingness to pay for vaccination.
not specified
Bock et al., 2016 assess elderlies’ willingness to pay for health insurance
and the factors influencing their preferences.
geriatrics
Bock et al., 2017 analyse the effect of longitudinal changes in several fac-
tors on the willingness to pay for health insurance.
geriatrics
Braun et al., 2000 evaluate the epidemiology of erectile dysfunction and
assess the willingness to pay for treatment of people
suffering from the disease and healthy subjects.
urology
[Günther et al., 2007] assess the burden of depressive disorders using the
stated preferences (willingness to pay, time-trade-off,




test the convergent validity of contingent valuation
methods by comparing the results of dicrete choice ex-





Table C.4 continued from previous page
reference content medical
discipline
Himmler et al., 2020 evaluate the cost-benefit ratio of early warning systems
for infectious diseases using a willingness to pay survey.
infectiology
Hodgkins et al., 2012 analyse factors influencing the adherence of patients
with ulcerative colitis.
gastroenterology





evaluate factors influencing the decision for foreign den-
tures or dental treatment abroad.
odontology
[König et al., 2005] evaluate the construct and concurrent validity of differ-
ent preference-based methods (EQ-5D, time-trade-off,





analyse the preferences (willingness to pay, side effects
and quality of life vs length of life) of patients, physi-
cians and healthy controls for melanoma treatment.
oncology
Lauer et al., 2020 evaluate longitudinal changes in parental willingness to





analyse preferences for health insurance by assessing
participants’ willingness to pay to obtain the status quo




evaluate the factors influencing the adoption of and
willingness to pay for mobile health apps.
not specified
Mayer et al., 2019 analyse preferences for testing of prostate cancer in af-




assess parents’ perceived risk of food-related hazards
and their willingness to pay to reduce this risk.
pediatrics
Pfarr & Schmid, 2016 conduct an empirical experiment to test the assump-
tion by Gouveia (1997) that preferences for the extent






evaluate preferences for different attributes (e.g. test
accuracy, test costs, identified diseases) of genetic test-
ing.
not specified
Radtke et al., 2009 evaluate the disease burden of vitiligo by assessing the





Table C.4 continued from previous page
reference content medical
discipline
Rasch et al., 2009 examine the factors influencing the willingness to pay
of menopausal-aged women for treatment.
gynaecology
Rasche et al., 2018 analyse preferences for features of a fall prevention
smartphone app and assess the willingness to pay for
it.
geriatrics
Schiffner et al., 2003 analyse and compare changes in different measures of
quality of life (willingness to pay, time-trade-off, disease
specific health state measures: PDI and PASI) in pso-
riasis patients.
dermatology
Schmitt et al., 2008 assess health utilities of patients suffering from psoriasis
and atopic eczema, and the general population using
different measures (willingness to pay, time-trade-off,
EQ VAS).
dermatology
Schomerus et al., 2008 assess the publics’ attitude (including their willingness





evaluate preferences of patients and healthy subjects
regarding the coverage of a diabetes pharmaceutical by
the health insurance and the associated financing forms
(health insurance contribution vs copayment).
endocrinology
Sikorski et al., 2012 analyse public attitudes and the determinants affecting
it regarding the prevention of obesity.
bariatrics
[Siol et al., 2017] analyse students’ preferences for oncological genetic
testing.
oncology
Thiel et al., 2013 assess the preferences of patients (university hospital
and non-university hospital) regarding an additional
funding for certified centers in the form of additional







analyse the effect of an educational course about health




Table C.4: Reviewed studies. Studies in German language in squared brackets.
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C.5. Theories on determinants of willingness to pay
C.5 Theories on determinants of willingness to pay
A discussion about different theories to explain individuals’ willingness to pay for
public environmental goods can be found at Liebe et al. (2011). They consider models
from economics, psychology and sociology. The determinants derived from their work
can be found in the table below. Whether these determinants also play a role regarding





















Theories Determinant Information Reference
Basic economic model Income Constrain by disposable income Carson et al., 2001
Use of public good Use value > existence value Carson et al., 2001
Theory of public goods Dilemma concern Free riding: “individual rationality leads to collec-
tive irrationality”
Kollock, 1998
Trust in other people’s
cooperation
Believe in willingness to pay of others increases
own willingness to pay
Ostrom, 2000
Fairness Deviation from economic assumptions Fehr & Schmidt, 1999
Attitude-behaviour paradigm Topic (e.g. environmen-
tal) concern
Economic: preferences (choices between alterna-
tives); Psychological/Sociological: attitudes (be-
haviour can be predicted by attitudes)
Green & Tunstall, 2001; Kahne-
man, Ritov, & Schkade, 1999
Theory of planned behaviour Intention Intention to perform a behaviour is determinant
of the respective behaviour
Ajzen, 1991
Attitude toward paying Subjective evaluation Studies regarding the three de-
terminants:




Perceived effort to perform behaviour Moisseinen, 1999; Pouta &
Rekola, 2001
Altruistic/moral behaviour General warm glow and
subjective obligation to
pay
Satisfaction leads to utility due to feelings of moral
obligation; good feeling might be independent
from whether people will be better off (embed-
ding effect: derived utility independent from quan-
tity of provided good; utility might vary between
goods
Kahneman & Knetsch, 1992
Norm-activation model Awareness of need and
responsibility to pay
Developed to explain (altruistic) helping be-
haviour; personal norm leads to moral obligation
when certain conditions are fulfilled: awareness of
need and responsibility for paying
Schwartz, 1977; Schwartz &
Howard, 1982
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